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 ABSTRACT 
QUANTIFICATION OF MITOCHONDRIAL MEMBRANE POTENTIAL 
 IN THE ISOLATED RAT LUNG USING R6G 
 
 
Anthony Cammarata, B.S. 
Marquette University, 2019 
Mitochondrial membrane potential (Δm) plays a key role in vital mitochondrial 
functions, and its dissipation is a hallmark of mitochondrial dysfunction in various cell 
types. The objective of this study was to develop an experimental and computational 
approach for estimating Δm in intact rat lungs using the lipophilic fluorescent cationic 
dye rhodamine 6G (R6G).  
 
Rat lungs were isolated and connected to a ventilation-perfusion system. The 
experimental Protocol consisted of three single-pass phases: loading, wash, and 
uncoupling, in which the lungs were perfused with R6G-containing perfusate, fresh R6G-
free perfusate, or R6G-free perfusate containing the mitochondrial uncoupler FCCP, 
respectively. This Protocol was carried out with or without lung perfusate containing 
verapamil, an inhibitor of the multi-drug efflux pump P-glycoprotein. 
 
Results show that the addition of FCCP resulted in an increase in R6G venous 
effluent concentration, and that this increase was larger in the presence of verapamil than 
in its absence. A physiologically based pharmacokinetic (PBPK) model for the 
pulmonary disposition of R6G was developed and used for quantitative interpretation of 
the kinetic data, including estimating Δm. The estimated value of Δm (-139 ± 21 (SD) 
mV and -128 ± 14 mV without and with verapamil, respectively) is consistent with that 
estimated previously in cultured pulmonary endothelial cells. These results demonstrate 
the utility of the proposed approach for quantifying Δm in intact functioning lungs.  
 
This approach has potential to provide quantitative assessment of the effect of 
injurious conditions on lung mitochondrial function, and to evaluate the impact of 
therapies that target mitochondria.  
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CHAPTER 1: INTRODUCTION, BACKGROUND, AND OBJECTIVE 
1.1 Clinical Motivation 
Mitochondria are commonly known as the powerhouse of the cell. For pulmonary 
endothelial cells, mitochondria produce approximately 80-85% of ATP needed for 
cellular functions (Bongard et al., 2013; Fisher AB et al., 1984). Mitochondria are also 
implicated in other important cellular functions, including apoptosis, calcium regulation, 
nitric oxide signaling, and are a primary source of reactive oxygen species (ROS) under 
physiological and pathophysiological conditions (Carraway et al., 2008; Sepehr et al., 
2013; Murphy et al., 2009; Bongard et al., 2013; Gan et al., 2011). Mitochondrial 
membrane potential (Δm) is a major component of the mitochondrial electrochemical 
transmembrane potential (proton motive force), which plays a key role in vital 
mitochondrial bioenergetics, metabolic, and signaling functions (Gan et al., 2011; 
Duchen et al., 2003).  In addition, mitochondrial dysfunction has been implicated in the 
pathogenesis of acute and chronic lung diseases (Audi et al., 2017; Fu et al., 2017; Ten et 
al., 2019; Ryter et al., 2018; Piantadosi et al., 2017; Audi et al., 2005; Sepehr et al., 
2013). Thus, the ability to quantify Δm in an intact functioning lung is essential to 
further the understanding of the role of mitochondrial dysfunction in the pathogenesis of 
lung injury and diseases, and to assess the efficacy of potential therapies that target the 
mitochondria. 
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Figure 1.1: Mitochondrial Dysfunction. This schematic shows how a decrease in 
mitochondrial membrane potential due to mitochondrial structural damage causes a 
decrease in ATP production and an increase in ROS production (Taken from Morris et 
al., 2015 with permission). 
 
 
1.2 Mitochondrial Membrane Potential: Electrochemical Gradient, ATP Production 
via Oxidative Phosphorylation 
For lung tissue, glucose is by far the most oxidizable substrate under 
physiological conditions (Bonora et al., 2012). The development of Δm and the synthesis 
of most mitochondrial ATP in the lung tissue start with the cellular uptake of glucose, 
followed by glycolysis and uptake of pyruvate into the citric acid or tricarboxylic acid 
(TCA) cycle, and ends with oxidative phosphorylation. During glycolysis, glucose is 
converted into two ATP, two NADH, and two pyruvate molecules, through a series of 
chemical reactions. The two pyruvate molecules then enter the TCA cycle where they are 
converted into two CO2 molecules, two ATP molecules, three NADH molecules, and one 
FADH2 molecule. Lastly the FADH2 and NADH molecules are reduced to NAD
+ and 
FAD to provide energy for the electron transport chain (ETC) in the form of electrons. 
The electrons that are produced create an electrochemical gradient. The transfer of 
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electrons in the ETC (complexes I-IV) makes it possible for protons to be pumped (at 
complexes I, III, and IV) against their concentration gradient, across the inner 
mitochondrial membrane, and into the mitochondrial intermembrane space. Hence, 
generating a proton gradient and furthermore generating a membrane potential across the 
inner mitochondrial membrane. The energy that is generated via the proton motive force 
(proton gradient and membrane potential) then drives the formation of 34 ATP from ADP 
at complex V. This process accounts for ~80-85% of ATP production in lung tissue. It 
should be noted that the total molecules of ATP created per glucose molecule is 
approximately 38. Therefore, a change in Δm is indicative of a change in lung tissue 
bioenergetics and mitochondrial function (Perry et al., 2011; Bonora et al., 2012). 
 
 
 
Figure 1.2: Cellular Bioenergetics. Schematic of the three main cellular processes 
(glycolysis, TCA cycle, and oxidative phosphorylation) that are involved in the 
conversion of glucose to ATP (Taken from Cunningham et al., 2004 with permission).  
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Figure 1.3: Mitochondrial ETC and ATP Synthesis Schematic Representation. The 
four complexes of the ETC are shown as well as ATP synthase. The ETC is important in 
regulating membrane potential (Taken from Nussbaum et al., 2005 with permission). 
 
 
Dissipation of Δm is a hallmark of mitochondrial dysfunction observed in 
various cell types, including pulmonary endothelial cells exposed to oxidative stress (Gan 
et al., 2011; Ma et al., 2018; Merker et al., 2009; Ruchko et al., 2005). Regulation of Δm 
is very important, not only for ATP production, but also for the transport of metabolites 
and ions in and out of the cells. Δm also has a large influence on the importing of 
precursors for enzymes and mitochondrial protein synthesis (Chen et al., 1988). 
Therefore, conditions that alter Δm could lead to mitochondrial dysfunction. Hence, the 
ability to quantify Δm is critical for understanding the pathogenesis of lung diseases for 
which mitochondrial dysfunction is a key factor. It is also important for the evaluation of 
the efficacy of novel therapies that target mitochondrial function. 
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1.3 Methods for Measuring Mitochondrial Membrane Potential 
Fluorescent lipophilic cations such as rhodamine dyes have been used for 
monitoring Δm, predominantly in reduced systems, including cultured cells and isolated 
mitochondria (Gan et al., 2011; Fu et al., 2017; Farkas et al., 1989; Perry et al., 2011; 
Aiuchi et al., 1982; Johnson et al., 1981; Scaduto et al., 1999). For most studies, this 
involved measurement of the intensity of fluorescent dyes within cultured cells or 
isolated mitochondria. Such measurements are confounded by the propensity of the dyes 
to undergo self-aggregation and quenching due to accumulation in mitochondria and 
cytosol (Gan et al., 2011).  
A study by Perry et al. included the development of a guide for using cationic 
probes for assessing Δm (Perry et al., 2011). The study provides an overview of cationic 
dyes that have been used to measure membrane potential, including TMRM, TMRE, and 
R123. The study also provides a step by step description on how cationic probes can be 
used properly to assess Δm.  
Previous studies have demonstrated the utility of cationic rhodamine dyes, 
including rhodamine 6G (R6G), to probe Δm mostly in isolated mitochondria and 
cultured cells (Gan et al., 2011; Scaduto et el., 1999; Johnson et al., 1981; Baracca et al., 
2003; Farkas et al., 1989; Mandalà et al., 1999; Aiuchi et al., 1982; Ehrenberg et al., 
1988; Gear et l., 1974; Solaini et al., 2007).  Mandalà et al. used R6G as a probe for 
plasma membrane potential in cultured bovine aortic endothelial cells (Mandalà et al., 
1999). They reported a linear relationship between the fluorescence intensity (F.I.) and 
the plasma membrane potential. The value of F.I. dropped following the addition of an 
inflammatory mediator and mitochondrial uncoupler (bradykinin), an ionophore 
6 
(nigericin), and/or the sodium-potassium ion pump inhibitor ouabain to the medium 
surrounding the cells. However, the addition of mitochondrial inhibitors (myxothiazol 
and oligomycin) to the medium did not affect F.I., which may suggest that R6G is not 
sensitive enough to changes in Δm (Mandala et al., 1999). However, other studies have 
shown that R6G is a mitochondrial specific dye and therefore can provide a measure of 
Δm (Johnson et al., 1981; Farkas et al., 1989).  For instance, Johnson et al. performed a 
study in which they monitored the relative Δm in living cells using cationic dyes 
including Rhodamine 123 (R123) and R6G. The results indicate that the fluorescence 
intensities associated with mitochondria were reflections of Δm (Johnson et al., 1981). 
R6G was also used to evaluate Δm in rat brain synaptosomes (Aiuchi et al., 1982). They 
demonstrated that R6G emission signal increased when depolarizing agents were added 
to the synaptosome suspension medium. In addition, the authors developed a modified 
Nernst equation that allows for the conversion of changes in R6G emission signal to 
membrane potential in mV (Aiuchi et al., 1982).  Ehrenberg et al. also demonstrated the 
utility of cationic dyes, including R6G, to probe membrane potential in various types of 
cultured cells (Ehrenberg et al., 1988). These studies clearly demonstrated the utility of 
R6G probing Δm in isolated mitochondrial and cultured cells. 
Huang et al. performed a study in which they developed a model that allowed 
them to better understand the relationship between Δm and measured fluorescence using 
the cationic dye R123 (Huang et al., 2007). They performed experiments in isolated 
cardiac mitochondria, and developed a computational model for quantitative 
interpretation of the resulting kinetic data. The model they used incorporated dye flux 
across a membrane as well as dye self-quenching. This was then added to a model of 
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mitochondrial electrophysiology which was used to estimate various parameters from the 
measured kinetic fluorescence data, including Δm.  
Gan et al. developed an experimental and computational approach for estimating 
mitochondrial and plasma (cellular) membrane potentials in cultured pulmonary arterial 
endothelial cells based on the extracellular disposition of the rhodamine dye tetramethyl 
rhodamine ethyl ester perchlorate (TMRE) and rhodamine 123 (R123) following its 
addition to the surrounding medium (Gan et al., 2011). Unlike other studies with cultured 
cells, Gan et al. evaluated the cellular uptake of each dye by measuring changes in its 
concentration in the surrounding medium instead of the concentration in cells (Gan et al., 
2011). For quantitative interpretation of the measured kinetic data, they developed a 
computational model that accounted for the dominant processes that determine the uptake 
of each dye, including plasma and mitochondrial membrane potentials and the multi-drug 
efflux pump P-glycoprotein (Pgp) for which TMRE and R123 are substrates (Gan et al., 
2011). Pgp pumps rhodamine dyes from the cytoplasm back into the surrounding 
medium. The objective of the present study was to develop a similar experimental and 
computational approach for estimating Δm in isolated perfused rat lungs using the 
lipophilic fluorescent cationic dye rhodamine 6G (R6G).   
Our choice of R6G for this study was motivated in part by the work of Roerig et 
al. who demonstrated significant R6G uptake and retention in isolated perfused rabbit 
lungs (Roerig et al., 2004), and by R6G’s high permeability in cell membranes of several 
types of cells, including pulmonary endothelial cells (Mandala et al., 1999).  
Scaduto et al. attempted to probe Δm in the intact heart by monitoring the surface 
emission fluorescent of Tetramethylrhodamine Methyl Ester Perchlorate (TMRM) 
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(Scaduto et al., 1999). Recirculated TMRM in perfusate was taken up and retained in the 
heart tissue. However, the results with mitochondrial uncouplers were difficult to 
interpret in part because of alteration in the fluorescent properties of TMRM in heart 
tissue due to the accumulation of TMRM in mitochondria. The experimental and 
computational approach described in this thesis overcomes this limitation by estimating 
the lung uptake and accumulation of R6G from the lung inlet and outlet R6G 
concentrations on passage through the pulmonary circulation instead of from lung surface 
measurements, and by using a computational PBPK model to account for the dominant, 
various vascular and tissue processes that determine the lung uptake and accumulation of 
R6G, including Δm.   
1.4 Objective and Specific Aims: 
Previous studies have quantified Δm predominately in isolated lung tissue 
mitochondria and to lesser extent in cultured lung cells using various cationic dyes, 
including rhodamine dyes (Gan et al., 2011; Scaduto et al., 1999; Perry et al., 2011; Chen 
et al., 1988; Johnson et al., 1981; Davis et al., 1985; Baracca et al., 2003; Huang et al., 
2007; Mandala et al., 1999; Aiuchi et al., 1982). Studies using these reduced systems are 
useful and provide important information which allows for the application of several 
tools of cell biology that are not applicable at the organ level. However, they cannot 
reproduce the multicellular environment in an intact functioning lung under physiological 
and pathophysiological conditions. Therefore, an approach for quantifying Δm in an 
intact functioning lung is needed. Thus, the objective of this thesis was to develop an 
experimental and computational approach for estimating Δm in isolated perfused rat 
lungs using the cationic fluorescent dye R6G. Thus, the specific aims of the thesis are to: 
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Aim # 1: evaluate the pharmacokinetics of R6G uptake in isolated perfused rat 
lungs. For this aim, experiments were carried out under different experimental conditions  
to identify the dominant processes that determine the uptake and retention of R6G on 
passage through the pulmonary circulation, and the sensitivity of R6G lung uptake to 
changes in Δm.  
Aim # 2: Develop a physiologically-based pharmacokinetic (PBPK) model for 
mechanistic and quantitative interpretation of the R6G spectroscopy kinetic data 
during passage through the rat pulmonary circulation. The lung uptake and retention of 
R6G on passage through the pulmonary circulation is the net result of multiple tissue and 
vascular processes, and hence estimating the mitochondrial membrane potential Δm or a 
change in Δm from the measured kinetic data is not straight forward. Thus, for this aim 
we developed a PBPK computational modeling for estimating parameters descriptive of 
those processes, including Δm, from the differences between lung inlet and outlet 
perfusate R6G concentrations under different experimental conditions. 
The results of the present study demonstrate the utility of the described 
experimental and computational approach for quantifying Δm in isolated perfused lungs.   
10 
CHAPTER 2: EXPERIMENTAL METHODS 
2.1 Materials 
 Rhodamine-6G (R6G), verapamil hydrochloride, Carbonyl cyanide 4-
(trifluoromethoxy) phenylhydrazone (FCCP), and all other reagents that are used in 
experiments were purchased from Sigma-Aldrich (St. Louis, MO). 
2.2 Isolated, Perfused Rat Lung Preparation 
 Animal Protocols described below were approved by the Institutional Animal 
Care and Use Committees of the Veterans Affairs Medical Center and Marquette 
University (Milwaukee, WI). 
 Adult male Sprague-Dawley rats (348 ± 3 g (SE), n = 59) were used for this 
study. Each rat was anesthetized with sodium pentobarbital (40-50 mg/kg 
intraperitoneal). The trachea was surgically isolated and cannulated, the chest opened and 
heparin (0.7 IU/g body wt.) injected into the right ventricle as previously described (Audi 
et al., 2018). The pulmonary artery and the pulmonary venous outflow were accessed via 
cannulas, then the heart/lungs were removed and connected to a ventilation-perfusion 
system.   
The Krebs-Ringer bicarbonate perfusate contained (in mM) 4.7 KCl, 2.51 CaCl2, 
1.19 MgSO4, 2.5 KH2PO4, 118 NaCl, 25 NaHCO3, and 5.5 glucose. The perfusate also 
contained 0.5% to 3% bovine serum albumin (BSA) plus 2.5% to 0% Ficoll to maintain 
consistent oncotic pressure. The perfusion system was primed with the perfusate 
maintained at 37oC and equilibrated with 15% O2, 6% CO2, balance N2 gas mixture 
resulting in perfusate PO2, PCO2 and pH of ~105 Torr, 40 Torr, and 7.4, respectively. 
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The lung was ventilated (40 breaths/min) with the above gas mixture with end-inspiratory 
and end-expiratory pressures of ~ 6 and 3 mmHg, respectively. The pulmonary artery and 
airway pressures were referenced to atmospheric pressure at the level of the left atrium 
and monitored continuously during the experiments. Perfusate was pumped (5 to 20 
ml/min) through the lung until it was evenly blanched and venous effluent was clear of 
visible blood before switching from single pass to recirculation mode.
 
Figure 2.1: Schematic of the Ventilation-Perfusion system used for IPL experiments. 
 
 
2.3 Hyperoxia treatment: 
 
Rat exposure to high oxygen environment (hyperoxia is a well-established animal 
model of clinical acute lung injury(Audi et al., 2005; Audi et al., 2016). Rats were placed 
in a sealed, temperature controlled, acrylic chamber 59 L chamber (33.0 × 58.3 × 30.5 
cm) and exposed to >95% oxygen (n = 2) for 48 hours. Within the chamber, carbon 
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dioxide levels were maintained at <0.5%, and temperature was maintained at 20-22°C. 
The rats were exposed to a 12:12 hours light-dark cycle. The O2 and CO2 levels were 
monitored to ensure the desired O2 concentration was achieved. This Protocol has been 
approved by the Institutional Animal Care and Use Committees of the Veterans Affairs 
Medical Center and Marquette University (Milwaukee, WI).  
2.4 Optical Imaging Systems 
 The RatioMaster fluorescence imaging system (Photon Technology International, 
HORIBA Scientific) was used to measure the R6G fluorescence (Figure 2.2). It uses a 
xenon bulb as the light source and is operated and controlled using custom software 
(FelixGX-4.3.2010) which is run using a windows operating system. For R6G, the 
monochromator was set to an excitation wavelength of 525 nm. The emission filter used 
(Chroma Technology Corporation, Bellows Falls, Vermont part # AT565/30m) has a 
wavelength of 565 ± 15 nm.  
 
Figure 2.2: PTI System used to gather experimental data 
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Table 2.1: Inhibitors and Uncouplers and their Target Sites.  
  Effects of Inhibitors and Uncouplers 
P-trifluoromethoxy 
carbonyl-cyanide phenyl-
hydrazone (FCCP) 
- Protonophore: uncouples the mitochondrial membrane potential by 
increasing the membrane’s permeability to protons. 
- Low concentrations depolarize the mitochondrial membrane while 
high concentrations may also depolarize the plasma membrane 
(Perry et al., 2011) 
Verapamil hydrochloride - Inhibitor of the plasma membrane Pgp pump.  
 
2.5 Experimental Protocols 
Protocol 1: Effect of R6G input concentration, pump flow, and perfusate % BSA on R6G 
extraction on passage through the lungs. 
For this Protocol, the objective was to assess the impact of R6G infused 
concentration, perfusate flow, perfusate % BSA, and connecting tubing from the 
perfusate reservoir to the lungs on R6G uptake on its passage through the pulmonary 
circulation.   
For the first set of experiments (n = 7), the perfusate included 0.5% BSA and 
2.5% Ficoll. Once the lungs were clear of blood, the pump was stopped, and the reservoir 
emptied and then refilled with 120 ml of perfusate. Two 1 ml reservoir samples were 
collected before and after the addition of R6G for a final concentration of 0.25 M.  
Those samples were used to determine the background signal and the actual R6G 
concentration in the reservoir. During the 10 minute lung perfusion (single pass mode) 
with the R6G-containing perfusate, two 1-ml lung venous effluent samples were collected 
every 20 seconds for the first 5 minutes and every minute for the last 5 minutes, with the 
first sample collected at time 40 seconds, where t = 0 seconds was the start of the loading 
phase. Based on the volume (~ 4 ml) of the system (lung + tubing) and flow, one would 
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expect no R6G signal in the venous effluent samples collected prior to 40 seconds.  
Samples were then centrifuged for 1 min (13,000 g, 4°C) to remove any cellular 
components and debris. The sample supernatant was then transferred into a plastic 
cuvette and its 565 nm emission signal (525 nm excitation) was measured using a 
RatioMaster fluorescence system (Photon Technology International, HORIBA Scientific, 
NJ) (Audi et al., 2018).  The emission filter was centered at 565 nm (ET565/30M, 
Chroma, VT) with a bandwidth of 30 nm. R6G optical density was determined and 
converted to concentration using a standard curve. The lung R6G extraction ratio (ER), a 
measure of the fraction of the input extracted on passage through the lungs, was 
determined using the following equation   
[ ]
1
[ ]
v
in
C
ER
C
= −      (2.1) 
where [Cv] is the R6G venous effluent concentration and [Cin] is the infused R6G 
concentration (0.25 M).  
 For some experiments (n = 3), the above Protocol was repeated with no lungs 
attached to the ventilation-perfusion system to assess the impact of the tubing connecting 
the reservoir to the lungs on the concentration of R6G in the venous effluent.  
Based on results from the above experiments (see Results section), it was 
determined that the R6G concentration in the venous effluent approached steady state at 
~6 min at a pump flow of 10 ml/min. Thus, for subsequent experiments under Protocol 1, 
venous effluent was collected only 6 min after the start of the pump for a flow of 10 
ml/min, and only 3 min and 12 min after the start of the pump for flows of 5 ml/min and 
20 ml/min, respectively.  
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Using the above Protocol with flow of 10 ml/min, we assessed the impact of R6G 
input (reservoir) concentration (0.125, 0.5, or 1.25 M) on R6G ER on passage through 
the pulmonary circulation. For 0.5 M and 1.25 M, venous effluent samples were first 
diluted with perfusate before measuring the emission signal to keep the intensity within 
the dynamic range of the fluorescence measuring system. In addition, we assessed the 
impact of changing perfusate % BSA (1%, 2%, or 3%) on R6G ER at 10 ml/min. For 
perfusate with BSA concentration of 1, 2 or 3%, the Ficoll concentration was 2%, 1% and 
0%, respectively, to maintain constant oncotic pressure. 
Using the above Protocol with perfusate of 0.5 % BSA and R6G reservoir 
concentration of 0.25 M, we assessed the impact of pump flow (5 ml/min or 10 ml/min) 
on R6G ER on passage through the pulmonary circulation.  
At the end of the above Protocol, the lungs were removed from the system and 
their wet weight was measured. The lungs were then dried, and the dry weight was 
measured. 
Protocol 2: Effect of treating isolated perfused lungs with verapamil and/or FCCP on 
R6G venous effluent concentration.  
Based on results from Protocol 1 (see Results section), the following experimental 
conditions were used for Protocol 2: perfusate with 0.5% BSA +2.5% Ficoll, 10 ml/min 
pump flow, and 0.25 M R6G reservoir concentration. These conditions result in lung 
steady-state ER of ~ 0.5, halfway within the dynamic range (0 to 1) of ER.  
Protocol 2 consisted of three single-pass perfusion phases: The loading phase in 
which the lungs were perfused with R6G-containing perfusate, the wash phase in which 
the lungs were perfused with fresh perfusate with no R6G, and the uncoupled phase in 
16 
which the lungs were perfused with perfusate containing the uncoupler FCCP and no 
R6G. Once the lungs were visually clear of blood, the flow was stopped to empty the 
perfusate in the reservoir and refilled with 120 ml of fresh perfusate. Before mixing the 
perfusate with the R6G, two 1-ml samples were collected to provide background signal 
for the loading phase. R6G stock (41.8 M) was then added to the perfusate in the 
reservoir for a final concentration of ~0.25 M. Two 1-ml samples were then collected 
from the reservoir to provide a measure of actual R6G lung input concentration for the 
loading phase. The remaining perfusate was used to perfuse the lungs during the 10 
minute loading phase.  During this phase, two 1-ml lung venous effluent samples were 
collected every 20 seconds for the first 5 minutes and every minute for the last 5 minutes, 
with the first sample collected 40 seconds after the start of the loading phase.  
At the end of the loading phase, the pump was stopped, and the reservoir quickly 
emptied and then refilled with R6G-free perfusate that was used to perfuse the lungs 
during the 3-minute wash phase. Prior to restarting the pump for the wash phase, two  
1-ml samples were collected from the reservoir and used as background samples for the 
wash phase. During the wash phase, two 1-ml venous effluent samples were collected 
every minute.  
 At the end of the wash phase, the pump was stopped again, and the reservoir 
emptied and then refilled with 75 ml of R6G-free perfusate containing the uncoupler 
FCCP at a concentration of 67 M. This concentration is high enough to ensure maximal 
dissipation of mitochondrial membrane potential (Zhao et al., 2013; Huang et al., 2018). 
This FCCP-containing perfusate was used to perfuse the lungs during the 7-min 
uncoupling phase. Prior to starting the pump for the uncoupling phase, two 1-ml samples 
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were collected to provide background signal. Venous effluent samples were collected 
every 20 seconds for the first two minutes and then every minute for the last 5 minutes 
during this phase.  
All samples from the three phases of Protocol 2 were centrifuged for 1 min 
(13,000 g, 4°C) to remove any cellular components and debris. The sample supernatant 
was then transferred into a plastic cuvette and its 565 nm emission signal (525 nm 
excitation) was measured (Audi et al., 2018). The R6G emission signal was determined 
and converted to concentration using a standard curve (see Appendix D).  
 
Figure 2.3: Cuvette and Fiber Optic Cable Holder 
 
 
At the end of Protocol 2, the lungs were removed from the system. Their wet 
weight was measured, the lungs were dried, and then their dry weight was measured.  
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2.5.1 Effects of Pgp inhibitors on R6G lung uptake 
 For a separate group of lungs, the above Protocol was carried out following the 
inhibition of the Pgp pump that pumps R6G out of the lungs. To inhibit the Pgp pump, 
Protocol 2 was modified as follows. Prior to the loading phase, perfusate containing 
verapamil (0.1 mM) Audi et al., 2018) was recirculated through the lungs for 3 minutes at 
10 ml/min after which time the flow was stopped, and the reservoir emptied and refilled 
with perfusate for the loading phase. In addition, perfusate used for all three phases 
included verapamil (0.1 mM). This concentration is high enough to ensure maximal 
inhibition of Pgp (Audi et al., 2018; Roerig et al., 2004). 
2.5.2 Effects of the uncoupler vehicle, DMSO 
 FCCP is soluble in dimethyl sulfoxide (DMSO). At high concentrations, DMSO 
is known to have negative effects (Yuan et al., 2014). Therefore, it was important to 
know if the concentration DMSO used had any effect on the lung uptake or washout of 
R6G. To determine the impact of DMSO alone on the lung uptake of R6G, the Protocol 
was repeated with just DMSO (0.05 % of the perfusate volume) added to the perfusate 
during the uncoupling phase of Protocol 2.     
2.5.3 Standard Curve 
For each experimental day, a standard curve was obtained as described below and 
used to convert R6G emission signal in collected samples to R6G concentration. Six 
tubes containing perfusate with known concentrations of R6G (0.5 M, 0.25 M, 0.125 
M, 0.0625 M, and 0.03125 M) were prepared. For each tube, a 2-ml sample was 
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collected then processed the same way as the samples collected from the lung’s venous 
effluent. Thus, each sample was centrifuged for 1 min (13,000 g, 4°C), after which its 
565 nm emission signal was measured. The standard curve was repeated with either 
verapamil, FCCP, or GF-120918 added to the samples prior to the addition of R6G to 
determine if the inhibitor/uncoupler and/or its vehicle interfered with the R6G emission 
signal. 
2.6 Effect of rat exposure to hyperoxia on R6G lung uptake:  
Protocol 2 was repeated on 2 lungs from rats exposed to >95% O2 for 48 hours. 
2.7 Statistical Analysis 
Statistical evaluation of data was carried out using SigmaPlot version 12.0 (Systat 
Software Inc., San Jose, CA). Values from different groups were compared using 
unpaired t-tests. The level of statistical significance was set at p < 0.05. Values are mean 
± SE unless otherwise indicated. 
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CHAPTER 3: EXPERIMENTAL RESULTS 
3.1 Rats body weights, lungs wet and dry weights, lungs wet/dry weight ratios, and 
pulmonary artery pressures: 
 Table 3.1 shows no significant differences between the body weights, lung wet 
and dry weights, the wet/dry ratios, and the pulmonary artery pressures of the rats used 
for Protocols 1 and 2. 
Table 3.1: Body weight, lung wet and dry weight, and wet/dry weight ratio, and 
pulmonary artery pressure for flow rate of 10ml/min.  
Protocol # 
Body weight 
(g) 
Lung wet 
weight (g) 
Lung dry 
weight (g) 
Wet/dry 
weight ratio 
Pulmonary 
artery 
pressure 
(mmHg) 
Protocol 1 
345.0 ± 2.8  
(n = 46) 
1.21 ± 0.02 
(n = 46) 
0.23 ± 0.02 
(n = 46) 
5.49 ± 0.10 
(n = 46) 
7.51 ± 0.15 
(n = 46) 
Protocol 2 
(normoxic 
rats)  
365.77 ± 7.8 
(n = 13) 
1.30 ± 0.03 
(n = 13) 
0.24 ± 0.01 
(n = 13) 
5.35 ± 0.06 
(n = 13) 
6.45 ± 0.24 
(n = 13) 
Protocol 2 
(hyperoxic 
rats) 
325.5 ± 7.42 
(n = 2) 
1.36 ± 0.07 
(n = 2) 
0.23 ± 0.01 
(n = 2) 
5.85 ± 0.004 
(n = 2) 
5.25 ± 0.88 
(n = 2) 
Values are mean ± SE. 
 
 
3.2 Rhodamine-6G (R6G) standard curve for experiments: 
Figure 3.1 shows example of the standard curves used to convert R6G emission 
fluorescent signal to R6G concentration.  Neither FCCP (67 M) nor verapamil (100 M) 
had a significant effect on R6G standard curves.  
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Figure 3.1: Standard curve for R6G. Perfusate BSA concentration was 0.5%. Values are 
mean ± SE (n = 7).  
 
3.3 Protocol 1: Factors that determine the lung uptake of R6G on passage through 
the isolated perfused lung 
Several factors determine the lung uptake of R6G, including perfusate protein 
concentration (% bovine serum albumin, or % BSA) and blood flow rate. Figure 3.2 
shows R6G ER after 6 min of perfusing lungs with 0.5% BSA perfusate containing 
0.125, 0.25, 0.5, or 1.25 M R6G at flow of 10 ml/min. These results show that for this 
concentration range, the lung ER is constant (dose-independent) consistent with first-
order kinetics for the various vascular and cellular processes that contribute to the lung 
uptake of R6G.  
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Figure 3.2: R6G lung extraction ratio (ER) after 6 min of perfusion (single pass) as a 
function of R6G input (reservoir) concentration. Pump flow = 10 ml/min, and perfusate 
BSA concentration was 0.5%. Values are mean ± SE (n = 6, 7, 4 and 7 for R6G 
concentrations of 0.125, 0.25, 0.5, and 1.25 M, respectively).  
 
 Figure 3.3 shows R6G ER after 6 minutes of lung perfusion (10 ml/min) with 
perfusate containing R6G (0.25 M) and 0.5%, 1%, 2%, or 3% BSA. The results show 
that ER decreased as the % BSA in perfusate increased, consistent with a decrease in the 
fraction of R6G that is available for lung uptake.  
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Figure 3.3: R6G lung extraction ratio (ER, solid bars) after 6 min of perfusion (single 
pass) as a function of perfusate %BSA. Pump flow = 10 ml/min. Values are mean ± SE 
(n = 10, 3, 3 and 4 for perfusate BSA of 0.5, 1.0, 2.0, and 3.0%, respectively. 
*significantly different from 0.5% BSA (P < 0.05, unpaired t-test), &significantly 
different from 1.0% (P < 0.05), and # significantly different from 2.0% (P < 0.05). 
 
Figure 3.4 shows that increasing pump flow (from 5 to 20 ml/min) decreased R6G 
ER, consistent with a decrease in the time available for R6G uptake. The ER was 
determined at times of 12 min, 6 min, and 3 min following the start of lung perfusion 
with R6G-contaning perfusate at flows of 5, 10, and 20 ml/min, respectively.  
24 
 
Figure 3.4: R6G lung extraction ratio (ER, solid bars) after 12 min, 6 min, and 3 min of 
perfusion (single pass) with pump flow set at 5, 10, or 20 ml/min, respectively. Values 
are mean ± SE (n = 4, 10, and 6 for flow of 5, 10, and 20 ml/min, respectively. 
*significantly different from ER at flow of 10 ml/min (P < 0.05, unpaired t-test). 
 
 Based on the results in Figures 3.2 – 3.4, we chose the following experiments 
conditions for Protocol 2: perfusate with 0.5% BSA (and 2.5% Ficoll) and flow rate of 10 
ml/min. These conditions result in lung steady state ER of ~ 0.5, halfway within the range 
(0 to 1) of ER.  
 Figure 3.5A shows R6G (0.25 M) ER on passage through the pulmonary 
circulation at pump flow of 10 ml/min and perfusate containing 0.5% BSA. The results 
show that ER approaches a steady-state value around 6 min (ER = 0.482 ± 0.013 (SE)) 
after the start of the perfusion of the lungs with R6G-containing perfusate. Thus at 6 min, 
~48% of the infused R6G was extracted or taken up on a single pass through the lungs.  
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The experimental Protocol for Figure 3.5A was repeated with the lungs removed 
from the perfusion system. The results in Figure 3.5B show that ER at steady state is not 
significantly different from zero. Thus, perfusion system tubing is not contributing to 
R6G ER on passage through the pulmonary circulation.  
 
Figure 3.5:  Panel A: R6G lung extraction ratio (ER) as a function of sampling time on 
passage through the pulmonary circulation. R6G reservoir concentration was 0.25 M, 
pump flow = 10 ml/min, and perfusate BSA concentration was 0.5%. Panel B: R6G 
tubing extraction ratio (ER) as a function of sampling time. R6G reservoir concentration 
was 0.25 M, pump flow = 10 ml/min, tubing volume = 4 ml, and perfusate BSA 
concentration was 0.5%. Values are mean ± SE (n = 7, 3 for panels A and B, 
respectively). 
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3.4 Lung venous effluent R6G concentrations during the three phases of Protocol 2:  
For each sample at a given sampling time, the measured intensity was determined 
as the average of the intensities acquired over a period of 5 seconds. For each of the three 
phases of the Protocol 2 experiments, the intensity of background samples was subtracted 
from the intensities of all subsequent samples. The slope of the standard curve for each 
day of experiments was then used to convert the measured intensities to R6G 
concentrations in the venous effluent at the time the sample was collected. The measured 
input R6G concentrations were slightly different from the desired 0.25 M, which 
created additional variability among the results of experiments using the same 
experimental Protocol.  To minimize this variability, the concentrations of all venous 
effluent samples were scaled by the ratio of 0.25 M to the measured R6G concentration 
of the input sample.   
Figure 3.6 shows R6G venous effluent concentrations during the three phases of 
Protocol 2. Results show that R6G venous effluent concentration decreased from ~ 0.13 
M during the loading phase to ~ 0.03 M during the wash phase after switching from 
perfusate containing 0.25 M R6G (loading phase) to perfusate with 0 M R6G (wash 
phase). Figure 3.6 also shows that perfusing the lungs with perfusate containing FCCP 
(~67 M) resulted in a rapid increase in the concentration of R6G in the venous effluent 
samples (uncoupling phase), consistent with the uncoupling of lung tissue mitochondria 
and the release of R6G that had accumulated in the mitochondria during the loading 
phase, driven by Δm. Thus, these data contain information about Δm, which was 
quantified using the computational model as described in Data Analysis chapter. 
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Figure 3.6: Solid symbols: R6G venous effluent concentrations during the loading phase, 
wash phase, and uncoupling phase using FCCP (67 M).  Values are mean ± SE (n = 7 
for loading and wash phases, and n = 5 for uncoupling phase). 
 
3.5 Effect of inhibitors of the multi-drug efflux pump P-glycoprotein (Pgp) on R6G 
lung uptake: 
 R6G is a known substrate for Pgp (Roerig et al., 2004). Thus, we evaluated the 
effect of the Pgp inhibitor verapamil on R6G venous effluent concentrations during the 
three phases of Protocol 2. Figure 3.7 shows the concentrations of R6G in the venous 
effluent following passage through lungs in which Pgp was inhibited by recirculating 
verapamil (0.1 mM) for 3 minutes prior to carrying out Protocol 2. In addition, verapamil 
(0.1 mM) was added to the perfusate during all three phases of this Protocol. The results 
show no significant increase in R6G uptake during the loading phase (as compared to 
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Figure 3.6), but a large increase in the concentration of R6G released from the lungs 
following the addition of FCCP to the perfusate (uncoupling phase). 
 Figure 3.7 also shows that adding just the vehicle (DMSO) for FCCP to the 
perfusate during the uncoupling phase had no effect on the concentration of R6G in the 
venous effluent compared to that during the wash phase. 
 
  
Figure 3.7:  Solid symbols: R6G venous effluent concentration in lungs following 
treatment with verapamil using Protocol 2. Values are mean ± SE. n = 6, 5, 5 for loading 
phase, wash phase, and uncoupling phase, respectively. Open symbols: R6G venous 
effluent concentration in lungs following treatment with verapamil using Protocol 2 with 
DMSO (FCCP vehicle) instead of FCCP added to the perfusate during the uncoupling 
phase. Values are mean ± SE (n = 2).  
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3.6 Effects of rat exposure to hyperoxia (>95% O2 for 48 hours) on R6G venous 
effluent concentrations using Protocol 2. 
 
Figure 3.8: R6G venous effluent concentration using Protocol 2 in lungs from 2 rats 
exposed to hyperoxia for 48 hrs.  
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CHAPTER 4: MODEL DEVELOPMENT 
4.1 Pharmacokinetic model of R6G pulmonary disposition 
For mechanistic and quantitative interpretation of the R6G kinetic data, a  
pharmacokinetic model was developed for the pulmonary disposition of R6G. The model 
was used to estimate parameters descriptive of the dominant factors that determine the 
lung uptake and retention of R6G, including Δm.    
 
 
Figure 4.1: Pharmacokinetic model of R6G lung uptake and retention on passage 
through the rat pulmonary circulation. The model consists of four regions: tubing, 
vascular, extravascular (non-mitochondrial), and mitochondrial with volumes Vtub, Vc, Ve 
and Vm, respectively. See below for definitions of various symbols and parameters. 
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The model (Figure 4.1) includes four regions, namely the tubing region, 
consisting of the tubing connecting the reservoir to the pulmonary artery, the lung 
vascular region, the extravascular (intracellular, non-mitochondrial) region, and the 
mitochondrial region, each with volume Vtub, Vc, Ve, and Vm, respectively. The model 
accounts for the hypothesized dominant vascular and/tissue processes that determine the 
lung uptake and retention of R6G on passage through the pulmonary circulation. Within 
the vascular region, the model accounts for the binding of R6G to BSA, which is 
assumed to be rapidly equilibrating with dissociation equilibrium constant Kd1. The 
model also accounts for the electrochemical gradients that drive the uptake of R6G from 
the vascular region to the extravascular region and from the extravascular to the 
mitochondrial region. R6G flux across plasma membrane (J1) or inner mitochondrial 
membrane (J2) is represented by a modified one-dimensional Goldman-Hodgkin-Katz 
equation (Gan et al., 2011; Huang et al., 2007). Furthermore, the model accounts for the 
Pgp pump which pumps R6G from the non-mitochondrial extravascular region back to 
the vascular region (Gan et al., 2011). The kinetic model makes no assumptions regarding 
the anatomical location of the Pgp protein, although it is assumed that Pgp transports 
R6G from the extravascular region back to the vascular region (Gan et al., 2011). At the 
concentration of R6G used (0.25 M), we assume that the pump follows first-order 
kinetics based on the data in Figure 3.2. Within the extravascular region, the model 
allows for slowly equilibrating R6G interactions (Gan et al., 2011). This could represent 
intracellular binding or sequestration in organelles, and is assumed to be a high-capacity, 
high-affinity pool for R6G (Gan et al., 2011). Within the mitochondria region, the model 
accounts for the binding of R6G to various proteins (Scaduto et al., 1999) which is 
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assumed to be rapidly equilibrating with dissociation equilibrium constant Kd3. The 
inhibitor verapamil is assumed not only to inhibit (competitive inhibition) Pgp- mediated 
R6G efflux, but also to compete (non-competitive inhibition) with R6G for binding sites 
in the extravascular region (Gan et al., 2011) (see Chapter 6). 
The rates of change in the concentrations of R6G in each of the four regions are 
described by the following system of differential equations, which were derived using the 
laws of mass balance and mass action. 
4.2 Derivation of Model Equations 
Glossary of terms: 
[Be]  Concentration of extravascular R6G binding sites (M) 
[Bc] = [BSA]  Vascular BSA concentration (%BSA) 
[Pm]  Concentration of mitochondrial R6G binding sites (M) 
[Ctub] Free R6G concentration within the tubing region (M) 
[Ce]  Free R6G concentration within the extravascular region (M) 
[CeBe]  Concentration of bound R6G within the extravascular region (M) 
[Cc]  Free R6G concentration within the vascular region (M) 
[CcBc]         Concentration of bound R6G within the vascular region (M) 
[ ]cC  Total concentration of R6G within the vascular region (M) 
[Cin]  Infused R6G concentration (M) 
[Cm]  Free R6G concentration within the mitochondrial region (M) 
[CmBm]        Concentration of bound R6G within the mitochondrial region (M) 
Q Flow rate (ml/min) 
J1  Dye flux across plasma membrane (nmol/(cm
2.min)) 
J2  Dye flux across inner mitochondrial membrane (nmol/(cm
2.min)) 
k1  Association rate constant of R6G - BSA binding in the vascular region 
(%BSA-1.min-1) 
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k-1  Dissociation rate constant of R6G-BSA binding within the vascular 
region (min-1) 
k2  Association rate constant of R6G – Be binding in the extravascular 
region (M-1.min-1) 
k-2  Dissociation rate constant of R6G – Be binding in the extravascular 
region (min-1) 
k3  Association rate constant of R6G - Bm binding in mitochondrial region  
 (M-1.min-1) 
k-3  Dissociation rate constant of R6G - Bm binding in mitochondrial region 
 (min-1) 
Kd1 = k-1/k1 Dissociation equilibrium constant for R6G - BSA binding in vascular 
region (% BSA) 
Kd3 = k-3/?̅?3  Dissociation equilibrium constant for R6G - Bm binding in the 
mitochondrial region 
?̅?2 = k2[Be] Apparent rate constant for R6G – Be binding in the extravascular 
region (min-1) 
?̅?3 = k3[Bm] Apparent rate constant for R6G - Bm binding in the mitochondrial 
region (min-1) 
Kpgp  Rate of efflux of R6G via Pgp pump from extravascular to vascular 
region (ml/min) 
P1  R6G permeability across plasma membrane (cm/min) 
P2  R6G permeability across mitochondrial membrane (cm/min) 
S1  Surface area of plasma membrane (cm
2) 
S2  Surface area of mitochondrial membrane (cm
2) 
V3  Apparent volume of mitochondrial region (ml) 
Vtub Physical volume of tubing region (ml) 
Ve Physical volume of extravascular region (ml)  
Vc  Physical volume of vascular region (ml) 
Vm  Physical volume of mitochondrial region = 0.02 Ve (ml) 
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α = ZF/RT  0.0374 mV-1 at 37 
o
C is a constant dependent on the universal gas 
constant (R), Faraday constant (F), R6G valence (Z), and absolute 
temperature (T).  
Δm  Mitochondrial membrane potential (mV) 
Δp  Plasma membrane potential (mV) 
 
4.2.1 Tubing Region 
( )
[ ]
[ ] [ ]tub in tub
tub
d C Q
C C
dt V
= −        (4.1) 
where [Cin] and [Ctub] are total (free + bound) concentration of R6G in reservoir and 
tubing regions, respectively. 
4.2.2 Vascular Region 
Rates of change in the concentrations of free, [Cc], and BSA-bound, [CcBc], R6G within 
the vascular region: 
( ) ( )1 1 1 1
[ ]
[ ] [ ][ ] [ ] [ ] [ ]cc c c c c c pgp e tub f c
d C
V V k C B k C B S J K C Q C C
dt
−= − − + + −  
     (4.2) 
( ) ( )1 1
[ ]
[ ] [ ][ ] [ ] [ ]c cc c c c c c tub b c c
d C B
V V k C B k C B Q C C B
dt
−= − + + −  
     (4.3) 
where Bc = perfusate % BSA, and [Ctub]f and [Ctub]b are the free and BSA bound R6G 
concentrations in the tubing region such that, 
 [Ctub] = [Ctub]f  + [Ctub]b  (4.4) 
and  
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Assuming rapidly equilibrating interactions between R6G and perfusate BSA 
then, 
1 1[ ] [ ][ ]c c c ck C B k C B− =   (4.6) 
1
1 1
[ ][ ]
[ ] [ ][ ] c cc c c c
d
C Bk
C B C B
k K−
= =   (4.7) 
where Kd1 is the R6G to BSA binding equilibrium dissociation rate constant. Let 
1
[ ]
[ ] [ ] [ ] [ ] 1 cc c c c c
d
B
C C C B C
K
 
= + = + 
 
  (4.8) 
then addition of equations 4.2 and 4.3 after substituting equations 4.7 and 4.8 for free and 
bound forms of R6G in the vascular region results in: 
( )1 1
[ ]
[ ] [ ] [ ]cc pgp e tub c
d C
V S J K C Q C C
dt
= − + + −   (4.9) 
and 
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  (4.10)  
4.2.3 Extravascular Region 
Rates of change in the concentrations of free, [Ce], and protein-bound, [CeBe], 
R6G within this region: 
( )2 2 2 2 1 1
[ ]
[ ] [ ] [ ]ec e e e e pgp e
d C
V V k C B k C S J S J K C
dt
−= − − + −   (4.11) 
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4.2.4 Mitochondrial Region 
Rates of change in the concentrations of free, [Cm], and protein-bound, [CmBm], 
R6G within this region: 
( )3 3 2 2
[ ]
[ ] [ ][ ]mm m m m m m
d C
V V k C B k C B S J
dt
−= − +   (4.14) 
( )3 3
[ ]
[ ] [ ][ ]m mm m m m m m
d C B
V V k C B k C B
dt
−= − +   (4.15) 
where [Bm] = protein concentration within mitochondrial region  
Assuming rapidly equilibrating interactions between R6G and Bm then: 
3 3[ ] [ ][ ]m m m mk C B k C B− =     (4.16) 
 
3
[ ]
[ ] mm m
d
C
C B
K
=     (4.17) 
where 3
3
3[ ]
d
m
k
K
k B
−= is R6G and Bm binding equilibrium dissociation constant. 
The addition of equations 4.14 and 4.15 after substituting equation 4.17 for 
[CmBm] results in 
   3 2 2
3
[ ] [ ]1
1 m mm
d
d C d C
V V S J
K dt dt
 
+ = = 
 
   (4.18) 
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where 3
3
1
1m
d
V V
K
 
= + 
 
 is the apparent volume of the mitochondrial extravascular 
region. 
4.2.5 System of governing ODE’s 
( )
[ ]
[ ] [ ]tub in tub
tub
d C Q
C C
dt V
= −    (4.20) 
( )1 1
[ ]
[ ] [ ] [ ]cc pgp e tub c
d C
V S J K C Q C C
dt
= − + + −    (4.21) 
( )2 2 2 2 1 1
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dt
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( )2 2
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[Ctub](t) and [ ]( )cC t are R6G total (free + bound) concentrations (M) at time t in 
the tubing and vascular regions, respectively;  [Ce](t) and [Cm](t) are R6G free 
concentrations in extravascular and mitochondrial regions at time t, respectively; 
38 
[CeBe](t) is R6G bound concentration in the extravascular region at time t; [Cin] is the 
R6G concentration in the reservoir; [Bc] is % BSA in perfusate; [Bm] is the concentration 
of R6G binding sites within the mitochondrial region; Q (ml/min) is pump flow; P1S1 
(ml/min) and P2S2 (ml/min) are products of R6G permeability (P) across plasma and 
mitochondrial membranes, respectively, and the surface area (S) of these membranes; 
Kpgp is Pgp-mediated dye efflux rate (ml/min); 
1
1
1
d
k
K
k
−=  (%BSA) is the dissociation 
equilibrium constant for R6G-BSA binding in the vascular region; 33
3[ ]
d
m
k
K
k B
−= is the 
dissociation equilibrium constant for R6G - Bm binding within the mitochondria region; 
3
3
1
1m
d
V V
K
 
= + 
 
 is the apparent volume (ml) of the mitochondrial region; ki and k-i are 
R6G and protein/binding sites association and dissociation rate constants, respectively, 
with Bc (i =1) and Bm (i = 3), respectively; 2 2[ ]ek k B=  (min
– 1) and k-2 (min
– 1) are rate 
constants for R6G binding and unbinding with binding sites Be within Ve, respectively, 
and [Be] is the concentration of those binding sites; α = ZF/RT = 0.0374 mV-1 at 37 
o
C is 
a constant dependent on gas constant, Faraday constant, R6G valence, and absolute 
temperature; Δm and Δp are mitochondrial and plasma membrane potential (mV), 
respectively. 
 
 
 
 
 
39 
Table 4.1: Model Parameters 
Symbol Description Units 
Kd1 = k-1/k1
  
Dissociation equilibrium constant for R6G-BSA 
binding in the vascular region %BSA 
2k  Apparent rate constant for R6G-Bc binding within 
the cytoplasm region  min
-1 
k-2 Dissociation rate constant of R6G-Bc binding 
within the cytoplasm region  min
-1 
3dK  Dissociation equilibrium constant for R6G-Bm 
binding within the mitochondria region  
Kpgp Rate of efflux of R6G via Pgp pump from 
cytoplasm to the vascular region ml/min 
P1S1   R6G permeability-surface area product across the 
plasma membrane  ml/min 
P2S2   R6G permeability-surface area product across the 
mitochondrial membrane ml/min 
Δm  Mitochondrial membrane potential 
mV 
 
 
The PBPK model R6G extraction ratio (ER) at a given time t, a measure of the 
fraction of the input that is extracted on passage through the lungs, is given by the 
following equation   
𝐸𝑅 = 1 −
[𝐶𝑒̅̅ ̅]
[𝐶𝑖𝑛]
    (4.27) 
 
4.3 Estimation of Model Parameters 
To reduce the number of unknown model parameters, the lung vascular volume (Vc) was 
set at 0.85 ml (Audi et al., 2003) and the lung extravascular volume (Ve) was set at 1.0 ml 
based on lung tissue water volume estimated from lung wet weight and wet-to-dry weight 
ratio (Audi et al., 2003). To break the correlation between Vm  and Δm, the ratio Vm/Ve 
was set to 0.02, consistent with a lower bound measured for this ratio in rat pulmonary 
endothelium (Gan et al., 2011). To break the correlation between P1S1 and Δp, the value 
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of Δp was set to that (-43 mV) estimated by Gan et al. in cultured pulmonary arterial 
endothelial cells (Gan et al., 2011). Furthermore, we assumed complete dissipation of 
Δm in the presence of FCCP at the concentration used (67 M) (Zhao et al., 2013; 
Huang et al., 2018), and complete inhibition of Pgp in the presence of verapamil at the 
concentration used (100 M) (Roerig et al., 2004).  Then, Δm, Kpgp, Kd1, Kd3, ?̅?2, k-2, 
P1S1, and P2S2 are the unknown model parameters (Table 4.1). The model-governing 
differential equations were solved numerically using the MATLAB (MathWorks) 
function “ode45,” which is based on an explicit Runge-Kutta formula. The equations 
were solved with the following initial (t = 0) conditions: [ ]cC (0) = [Ce](0) = [Cm](0) = 0 
and [Ctub](0) = [Cin] for Protocol 1 and loading phase of Protocol 2, and [Ctub](0) = 0 for 
wash and uncoupling phases of Protocol 2.  
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CHAPTER 5: DATA ANALYSIS 
5.1 Experimental Data Analysis  
Data analysis was performed in Excel and Matlab using text files exported from 
PTI’s Felix software. 
5.1.1 Standard Curve 
For each standard R6G concentration, the R6G fluorescent intensity was 
determined from the average intensity measurements acquired over a period of 5 seconds. 
The average intensity of the sample with no R6G added was considered background, and 
this intensity was subtracted from the intensities of samples with different R6G 
concentrations. The resulting intensities were then plotted against the known R6G 
concentrations added to each standard sample. As shown in Figure 5.1, linear regression 
was then used to estimate the slope of the standard curve which was then used to convert 
R6G intensity in each lung to R6G concentration.  
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Figure 5.1: Representative standard curve for R6G. This is done to have a way of 
converting the recorded emission values from experimentation to concentration values. 
This procedure was performed for every experimental data set. Values are mean ± SE (n 
= 7). 
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5.2 Fit of PBPK model to data 
 
Figure 5.2: R6G lung extraction ratio (ER, solid bars) after 6 min of perfusion (single 
pass) as a function of perfusate %BSA. Pump flow = 10 ml/min. Values are mean ± SE 
(n = 10, 3, 3 and 4 for perfusate BSA of 0.5, 1.0, 2.0, and 3.0%, respectively. Open bars 
are model fit values. *significantly different from 0.5% BSA (P < 0.05, unpaired t-test), 
&significantly different from 1.0% (P < 0.05), and # significantly different from 2.0% (P < 
0.05). 
Line (simultaneous fit of protocol 2 no verp + BSA ER data)
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Figure 5.3: R6G lung extraction ratio (ER, solid bars) after 12 min, 6 min, and 3 min of 
perfusion (single pass) with pump flow set at 5, 10, or 20 ml/min, respectively. Values 
are mean ± SE (n = 4, 10, and 6 for flow of 5, 10, and 20 ml/min, respectively. Open bars 
are model prediction. *significantly different from ER at flow of 10 ml/min (P < 0.05, 
unpaired t-test). 
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Figure 5.4:  Panel A: R6G lung extraction ratio (ER) as a function of sampling time on 
passage through the pulmonary circulation. R6G reservoir concentration was 0.25 M, 
pump flow = 10 ml/min, and perfusate BSA concentration was 0.5%. Panel B: R6G 
tubing extraction ratio (ER) as a function of sampling time. R6G reservoir concentration 
was 0.25 M, pump flow = 10 ml/min, tubing volume = 4 ml, and perfusate BSA 
concentration was 0.5%. Solid line is model prediction. Values are mean ± SE (n = 7, 3 
for panels A and B, respectively). 
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Figure 5.5: Solid symbols: R6G venous effluent concentrations during the loading phase, 
wash phase, and uncoupling phase using FCCP (67 M).  Values are mean ± SE (n = 7 
for loading and wash phases, and n = 5 for uncoupling phase). Solid line is model fit to 
data. 
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Figure 5.6:  Solid symbols: R6G venous effluent concentration in lungs following 
treatment with verapamil using Protocol 2. Values are mean ± SE. n = 6, 5, 5 for loading 
phase, wash phase, and uncoupling phase, respectively. Open symbols: R6G venous 
effluent concentration in lungs following treatment with verapamil using Protocol 2 with 
DMSO (FCCP vehicle) instead of FCCP added to the perfusate during the uncoupling 
phase. Values are mean ± SE (n = 2). Solid line is model fit to mean of the solid symbols. 
Dashed line is model prediction of the open symbols. 
 
 
For data from Protocol 1, the results (Figure 5.3) are expressed as the extraction 
ratio (ER) as a function of flow rate. The flow rate R6G extraction data in Figure 5.3 
contains information about PS1. Whereas the R6G extraction data in Figure 5.6 contain 
information about kpgp. All the data also contain information about kd2, kd3, and ∆𝑚.  
To characterize the pulmonary pharmacokinetics of R6G, information about its 
permeability across the plasma membrane is needed. This information can be obtained by 
evaluating the impact of changing perfusate flow rate (and hence pulmonary transit time) 
on the lung ER of R6G. A small change in ER with flow would suggest that cell 
membrane permeability for R6G is relatively high, whereas a large change would be 
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consistent with a significant barrier for the uptake of R6G on passage through the 
pulmonary circulation.  
5.3 Estimation of model parameters 
The first step in the procedure to estimate the unknown parameters was to fit the 
mean kinetic data of Protocol 2 in the absence of verapamil (Figure 5.5) and the ER 
values at the four different perfusate %BSA (Figure 5.2) simultaneously. The objective 
was to obtain an estimate of Kd1 for R6G binding with perfusate BSA, and initial 
estimates of the other unknown parameters (Table 4.1). The model fitting was done in 
MATLAB® using the lsqcurvefit function to implement the trust-region-reflective 
algorithm, an iterative optimization algorithm that readily incorporates bounds on the 
values of the parameters.  
The estimated values of model parameters that best fit the data along with the 
model fits are shown in Table 5.1 and Figures 5.2 and 5.5, respectively. Based on the 
estimated values of Kd1 (0.32 %BSA, Table 2), R6G is ~61% bound to BSA in perfusate 
that includes 0.5% BSA.  
 
Table 5.1: Values of model parameters estimated by simultaneously fitting the data in 
Figures 5.2 and 5.5. 
 
P1S1 
(ml/min) 
P2S2 
(ml/min) 
Kpgp 
(ml/min) 
2
k  
(ml/min) 
k-2 
(min-1) 
Kd3 Δm 
(mV) 
Kd1 
(%BSA) 
45.40 0.71 6.19 11.13 0.1223 0.0327 - 118.21 0.32 
 
 
Next, Kd1 was fixed at the value in Table 5.1, and the other model parameters 
were estimated from the kinetic data from individual Protocol 2 experiments without or 
with verapamil added to the perfusate (Figures 5.5 and 5.6). In the presence of verapamil, 
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the value of Kpgp was set to zero. The estimated values of the model parameters are 
shown in Table 5.2 and Figures 5.5 and 5.6. The ability of the model to fit data from 
individual experiments is exemplified in Figure 5.7 for Protocol 2 with and without 
verapamil added to the perfusate. The estimated values of the model parameters show 
that verapamil not only inhibited Pgp, but also had a significant effect on the binding of 
R6G in the extravascular region (see Chapter 6).  
 
Table 5.2: Values of model parameters estimated by fitting model to kinetic Protocol 2 data 
from individual lungs in absence or presence of verapamil in the perfusate   
 P1S1 
(ml/min) 
P2S2 
(ml/min) 
Kpgp 
(ml/min) 
2
k  
(ml/min) 
k-2 
(min-1) 
Kd3 Δm  
(mV) 
R6G 48.81 
± 0.66 
0.82 ±  
0.04 
8.98 ± 
1.55 
12.67 ± 
0.58 
0.111 ± 
0.005 
0.023 ± 
0.002 
- 123.8 
± 0.8 
R6G + 
verapamil 
46.69 ± 
0.32* 
1.12 ± 
0.16 
0 7.00 ± 
0.51* 
0.172 ± 
0.022* 
0.016 
±0.002* 
- 130.6 
± 5.2 
Values are mean ± SE (n = 6 and 5 without and with verapamil, respectively).  *different 
from without verapamil (t-test, P < 0.05). Kd1 (%BSA) was fixed at the value in Table 
5.1. 
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Figure 5.7:  Solid symbols: Representative R6G lung venous effluent concentration vs. 
time data using Protocol 2 without (Panel A.) or with (Panel B.) lung treatment with 
verapamil. Solid line is model fit.  
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5.4 Model Validation 
To validate the model, we assessed its ability to predict experimental data that 
were not used for model development, including estimation of the values of the unknown 
model parameters. To that end, we evaluated the ability of the model to predict the 
experimental data in Figure 5.5 at the different pump flows. The kinetic model and the 
mean of the estimated best fit values of model parameters without verapamil (Table 5.2) 
were evaluated by predicting the effect of pump flow on R6G ER at flows of 5 ml/min 
and 20 ml/min (Figure 5.3). The results in Figure 5.3 show that the predicted ER values 
are close to the measured values, providing support for the model and the estimated 
values of the model parameters (Table 5.2). 
5.5 Measures of estimability of the model parameters  
 The estimability of the model parameters from the Protocol 2 kinetic data in 
Figures 5.5 and 5.6 was evaluated using a Monte Carlo approach and sensitivity analysis 
(Dutta et al., 1997; Bassingthwaighte et al., 1984). For the Monte Carlo approach, the 
model was fit to the Protocol 2 mean data without (Figure 5.5) or with (Figure 5.6) 
verapamil and was repeated 100 times with different initial values for the model 
parameters. The initial values were determined as the mean of the estimated best fit 
values given in Table 5.2 (without or with verapamil) + a uniformly distributed random 
value within ± 30% of this mean. The resulting estimated values from the 100 fits are 
shown in Table 5.3.  The results show smaller standard deviation (SD) for ΔΨm from data 
with verapamil (Figure 5.6) compared to no verapamil (Figure 5.5) added to the perfusate 
(see Chapter 6).  
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Table 5.3: Estimated values of model parameters (Monte Carlo approach): 100 different 
fits to mean data in the absence or presence of verapamil with the initial values of model 
parameters equal to the mean values of the fits to individual experiments (Table 5.2) ± a 
uniformly-distributed random value within ± 30% of this mean error 
 P1S1 
(ml/min) 
P2S2 
(ml/min) 
Kpgp 
(ml/min) 
2
k  
(ml/min) 
k-2 
(min-1) 
Kd3 Δm 
(mV) 
R6G 49.37 
± 7.27 
0.769 
± 0.156 
13.504 ± 
4.768 
14.78 ± 
2.37 
0.118 
± 
0.013 
0.028 
± 
0.010 
- 138.82 
± 20.67 
R6G + 
Verapamil 
49.19 
± 9.11 
1.178 
± 0.326 
0 7.21 ± 
0.63 
0.168 
± 
0.019 
0.015 
± 
0.003 
- 128.09 
± 13.86 
Values are mean ± SD 
The estimability of the model parameters from the Protocol 2 kinetic data in 
Figures 5.5 and 5.6 was also evaluated using sensitivity analysis. Parameters values were 
set to the mean of the best fit values estimated from the individual experiments (Table 
5.2). Figure 5.8 shows the corresponding sensitivity functions that represent the 
normalized change in the model-fit for a 1% change in the value of each free parameter. 
The results show similarly shaped sensitivity functions for P2S2 and Δm during the 
loading phase of Protocol 2, but different shapes during the wash and uncoupling phases. 
For the wash phase, the sensitivity function for P2S2 is close to zero, but different from 
zero for Δm. This relative similarity between the sensitivity functions of P2S2 and Δm 
during the loading and uncoupling phases may reflect a correlation between those two 
parameters and is consistent with the relatively large SD for both parameters in Table 5.3.  
See Chapter 6 for potential approaches to reduce this correlation. 
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Figure 5.8:  Model parameter sensitivity functions using Protocol 2 without (top panel) 
or with (bottom panel) verapamil. The sensitivity functions show the change in the model 
solution given a 1% increase in the value of a given model parameter. Each plot is 
normalized to its maximum value. 
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5.6 Sensitivity of Protocol 2 experiments to depolarization and hyperpolarization of 
Δm:  
To assess to ability of Protocol 2, without and with verapamil added to the 
perfusate, to detect a change in Δm, model simulations (Figure 5.8) were generated 
using the mean values of the estimated parameters in Table 5.2. The value of Δm was 
decreased (depolarization) or increased (hyperpolarization) with the values of the other 
model parameters set to the mean values in Table 5.2. Results show that the uncoupled 
phase is highly sensitive to a change in Δm, and that the sensitivity to Δm 
depolarization is larger in the presence of verapamil than in its absence. 
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Figure 5.9:  Model predictions of the sensitivity of lung R6G venous effluent 
concentrations using Protocol 2 to depolarization or repolarization of mitochondrial 
membrane potential without (top panel) or with (bottom panel) verapamil. Mean values 
of model parameters in Table 5.2 were used to generate these simulations.  
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CHAPTER 6: DISCUSSION AND CONCLUSIONS 
6.1 Overview and Interpretation of Results: 
This thesis describes a fluorometric experimental and computational approach for 
evaluating lung tissue Δm in isolated perfused rat lungs using the lipophilic cationic dye 
R6G. The approach is based on changes in the lung R6G inlet-outlet perfusate 
concentrations before and after uncoupling the lung tissue mitochondria. A 
pharmacokinetic model was developed and used for quantitative interpretation of the 
resulting kinetic data and for estimating parameters that describe the dominant processes 
that determine the disposition of R6G on passage through the rat lungs, including Δm. 
The model and estimated parameters were validated by determining their ability to 
reasonably predict the effect of pump flow on the extraction ratio of R6G on passage 
through the lungs over a wide range of flows. The estimated value of Δm is consistent 
with that estimated from cultured pulmonary arterial endothelial cells (Gan et al., 2011).  
 The lung is a complex organ with multiple vascular and tissue processes 
determining the pulmonary disposition of R6G. To overcome this complexity, we used 
inhibitors and a variety of perfusion conditions to target the dominant processes that are 
hypothesized to determine the pulmonary disposition of R6G. This provided us with 
discriminating information about those processes. In addition, we used a computational 
model to interpret the data. Computational modeling provides a mechanistic and 
quantitative framework that accounts for those processes and allows us to estimate 
parameters descriptive of those processes, including Δm (Gan et al., 2011; Roerig et al., 
2004; Gan et al., 2011). The pharmacokinetic model developed in the present study is an 
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extension of the model developed by Roerig et al. for the disposition of R6G in rabbit 
lungs to evaluate the lung activity of Pgp (Roerig et al., 2004). Unlike the model 
developed in the present study, their model did not account for the role of Δm and Δp in 
the lung uptake and retention of R6G. For the study by Roerig et al., the objective was to 
evaluates the kinetics of the Pgp pump in isolated perfused rabbit lungs. 
Generally speaking, a single experimental condition or data set of the type 
presented here does not contain sufficient information to estimate the parameters of the 
pharmacokinetic model (Gan et al., 2011; Roerig et al., 2004; Gan et al., 2011). Instead, a 
diverse set of experimental conditions was needed to provide sufficiently discriminating 
information about the dominant processes that determine R6G uptake and retention in the 
lung.  This approach is needed to break the correlation between some of the model 
parameters that describe these processes. Both measures of estimability of model 
parameters from the kinetic data using Protocol 2 without or with verapamil (Figure 5.8 
and Table 5.3) suggest a relatively high correlation between Δm and P2S2 during the 
loading and uncoupling phases, but not during the wash phase. This observation is 
consistent with the relatively high standard deviation of the estimated values of Δm and 
P2S2 using the Monte Carlo approach (Table 5.3). One approach to reduce this correlation 
would be to extend the duration of the wash phase or to include additional experimental 
data, such as Protocol 2 under a different flow. 
Previous studies using cationic dyes to probe Δm have predominately been 
carried out in reduced systems, including isolated mitochondria and cultured cells (Gan et 
al., 2011; Audi et al., 2017; Perry et al., 2011; Aiuchi et al., 1982; Johnson et al., 1981; 
Scaduto et al., 1999; Mandala et al., 1999; Huang et al., 2007; Chen et al., 1988; Agard et 
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al., 2009; Davis et al., 1985; Baracca et al., 2003). Gan at al. developed an approach for 
quantifying Δm and plasma membrane potential in cultured pulmonary endothelial cells 
based on the disposition of rhodamine dyes in the medium surrounding the cultured cells 
(Gan et al., 2011). The experimental and computational approach described in the present 
study is an extension of their approach to isolated perfused rat lungs. The estimated value 
of Δm in the present study (-124 ± 1 (SE) mV and -131 ± 5 mV without and with 
verapamil, respectively) is consistent with that estimated by Gan et al. in cultured 
pulmonary endothelial cells (-130 ± 3 (SE) mV and -133 ± 1 mV) using rhodamine 123 
and TMRE, respectively) (Gan et al., 2011).  
For the present study, R6G was chosen since its uptake is rapid enough to 
accumulate within the lung tissue on a single pass through the pulmonary circulation 
(Roerig et al., 2004). This is in part due to its relatively high octanol/water partition 
coefficient compared to that of other rhodamine dyes such as R123 (Mottram et al., 
2012). Our data are consistent with the large (relative to flow) estimated values of P1S1 
for R6G (Table 5.2) and its high permeability in cell membranes in a wide range of cells, 
including endothelial cells (Mandala et al., 1999; Loetchutinat et al., 2003). Furthermore, 
under the experimental conditions used in the present study (10 ml/min flow, 0.5% BSA, 
and 0.25 M input concentration), R6G ER is ~ 0.5 (Figure 5.4A), which is midway 
within the 0 to 1 dynamic range for ER, and hence optimal for detection of depolarization 
or repolarization of Δm. 
Previous studies evaluated the effect of R6G on mitochondrial functions 
(Williams et al., 1999;  Gear et al., 1974). Using isolated rat liver mitochondria, ARL 
Gear showed that R6G at concentration > 1 M can have a significant inhibitory effect 
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(Ki ~ 3 M) on mitochondrial membrane potential and ATP-supported calcium 
accumulation. Using cultured human skin fibroblasts, Williams et al. showed that cells 
cultured (3-8 days) in R6G-containing culture medium experienced poor growth for R6G 
concentrations as low as 1.2 M. In addition, this prolonged cell treatment with R6G 
significantly decreased the number of intact mitochondrial and electron transport chain 
enzyme activities. For the present study, the concentration of R6G in the lung perfusate 
was 0.25 M, well below the 1 M at which toxic effects on mitochondrial functions 
were observed, and the lungs were perfused with this concentration for 10 minutes. In 
addition, the binding or R6G to BSA in perfusate decreased the concentration of perfusate 
R6G available for cellular uptake to closer to 0.125 M. Thus, for the present study the 
experimental conditions, including the chosen R6G concentration, minimized the 
potential effects of R6G on mitochondrial functions. 
Comparison of the data in Figure 5.7 shows that lung treatment with verapamil 
had no effect on the uptake and retention of R6G during the loading phase, although it 
had a significant effect during the uncoupling phase of Protocol 2. Model simulations 
(not shown) revealed that this increase cannot be explained by just the inhibition of the 
Pgp pump, and in fact the R6G efflux concentration was predicted to decrease during the 
uncoupling phase. The estimated values of the model parameters (Table 5.2) suggest that 
verapamil not only inhibited the Pgp pump, but also competed with R6G for the slowly 
equilibrating binding sites in the extravascular region. This effect countered the increase 
in lung uptake of R6G due to the inhibition of the Pgp pump, and allowed the R6G 
released from the mitochondrial region into the extravascular region during the 
uncoupling phase to diffuse quickly into the vascular region driven by the increase in the 
60 
concentration gradient of free R6G across the plasma membrane (Roerig et al., 2004; Cho 
et al., 2000).   
Unlike the results of the present study, Roerig et al. showed a significant increase 
in R6G lung uptake in the presence of verapamil compared to in its absence in isolated 
perfused rabbit lungs (Roerig et al., 2004). This could be due to the relatively large rate 
of Pgp-mediated R6G efflux compared to that for cytosolic R6G binding in rabbit lungs 
(1.44 min-1 vs. 0.23 min-1) (Roerig et al., 2004). For rat lungs, the rate of Pgp-mediated 
R6G efflux was comparable to that for cytosolic R6G binding (13.5 min-1 vs. 14.8 min-1) 
(Table 5.2). In addition, for the rabbit lungs, the rate of Pgp-mediated R6G efflux is an 
order of magnitude larger than the rate of R6G efflux by diffusion across the cell 
membrane, whereas in the rat lungs P1S1 was much larger than the rate of Pgp-mediated 
efflux (Table 5.2).  
One question that could be addressed using the proposed computational model is 
the sensitivity of Protocol 2 to a change in Δm in the presence or absence of verapamil. 
Model simulations (Figure 5.8) show that Protocol 2 in the presence of verapamil has a 
higher sensitivity to depolarization of Δm than in the absence of verapamil. This is in 
part due to a decrease in the competition between cytoplasm binding and mitochondria 
for free R6G in the cytoplasm. This and the reduction in the number of unknown 
parameters for Protocol 2 in the presence of verapamil suggest that Protocol 2 in the 
presence of verapamil is preferable for evaluating Δm in isolated perfused lungs for 
conditions expected to cause dissipation of Δm. 
Scaduto et al. attempted to probe Δm in isolated perfused rat hearts by 
monitoring the surface emission fluorescence of the cationic rhodamine dye tetramethyl 
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rhodamine methyl ester perchlorate (TMRM) following its addition to perfusate that was 
recirculated through the heart (Scaduto et al., 1999). However, the results with a 
mitochondrial uncoupler and substrate-free perfusate were difficult to interpret in part 
because of alteration in the fluorescent properties of TMRM in heart tissue due to 
accumulation of TMRM in both mitochondria and cytosol (Scaduto et al., 1999). The 
approach described in the present study overcame this limitation by 1) determining the 
lung uptake of R6G from the lung inlet and outlet R6G perfusate concentrations on 
passage through the pulmonary circulation instead of from lung surface measurements, 
and 2) by using computational modeling for quantitative interpretation of the resulting 
kinetic data and for estimating parameters descriptive of the dominant vascular and tissue 
processes that determine lung uptake and accumulation of R6G, including Δm.  
Hough et al. (JCI 4(3): e124329, 2019) used the fluorescent cationic dye 
tetramethylrhodamine ethyl ester (TMRE) to assess the effect of acute chemical lung 
injury on mitochondrial membrane potential of microvascular endothelial cells in isolated 
perfused mouse lungs. For that study, the lungs were loaded with TMRE by recirculated 
perfusate containing TMRE (2 M) for 20 min, followed by a 10-min buffer washout. 
Acute chemical injury was then induced by microinfused concentrated hydrochloric acid 
(HCl) in the alveolar lumen using alveolar micro puncture technique. Confocal 
microscopy was used to measure TMRE fluorescent intensity in micro vessels in the 
injured local region before and after injury with HCl. Change in measured TMRE 
fluorescence was then used as measure of a change in Δm. Although this approach 
allows for assessing a change in endothelial TMRE fluorescence, it has many limitations. 
First, it provides a measure of local change in TMRE fluorescence, which may not be 
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reflective of the overall change in the lung. This especially true for many lung injury or 
disease, which is heterogeneous affecting some lung regions/lobes more than others. 
Second, a common pitfall in interpreting such data is that the logarithmic form of the 
Nernst equation specifies that changes in fluorescence intensity are not linearly 
proportional to changes in Δm. For instance, a 50% decrease in ratio to mitochondrial to 
cytosolic dye fluorescence translates to just 17% change in Δm. Third, this approach 
does not account for the fact that dyes such as TMRE are also Pgp substrates. For cell 
types that have few or no multidrug transporters, this may be of minimal importance, but 
multidrug transporters perform a key function in the pulmonary endothelium (Roerig et 
al., 2004). A change in Pgp activity will have an effect on TMRE mitochondrial 
fluorescence intensity. This effect could be misinterpreted to represent a change in Δm. 
Fourth, this approach requires loading the cells with TMRE by recirculating it through 
the lungs at a relatively high concentration (2 M) for 20 min. TMRE accumulates in the 
mitochondrial matrix driven by Δm. The approach is confounded by the propensity of 
dyes such TMRE to undergo self-aggregation, quenching, and photobleaching and/or to 
exert phototoxic effects (Scaduto et al., 1999). This affects the utility of a change in 
measured mitochondrial TMRE fluorescence as an index of a change in Δm. The 
experimental and computational approach described in this thesis overcomes many of 
these limitations. 
For the present study, the value of Δp was fixed to that estimated by Gan et al. 
from cultured pulmonary endothelial cells (Gan et al., 2011). Previous studies have 
demonstrated a key role for Δp in regulating channel-mediated calcium entry in 
response to mechanical stimuli, oxidative stress, ischemia, and hypoxia (Campbell et al., 
63 
1991; Koliwad et al., 1996; Paffett et al., 2007; Stevens et al., 1994; Chatterjee et al., 
2006). As such, Δp could be altered by injury or disease.  One could obtain information 
about Δp by evaluating the impact of its depolarization on R6G lung uptake and 
retention. This could be done by perfusing the lungs with perfusate containing high 
potassium as was done by Gan et al. in cultured endothelial cells (Gan et al., 2011) or by 
Al-Mehdi et al. in isolated perfused rat lungs (Al-Mehdi et al., 1997). Another approach 
would be to use fluorescent dyes sensitive to Δp such as the anionic probe bis-oxonol 
(Al-Mehdi et al., 1997; Zhang et al. 2005).  
The lung vascular volume (Ve) was also fixed to that estimated from normal rat 
lungs (Audi et al., 2003). Lung injury, including oxidative stress, has been shown to 
change lung vascular and extravascular volumes (Audi et al. 2005; Crapo et al., 1980). 
An independent estimate of Ve could be obtained using lipophilic amines and indicator 
dilution methods in isolated perfused lungs as previously described (Audi et al., 2005; 
Ramakrishna et al., 2010).  
The lung consists of 40 different resident cell types (Kotton et al., 2014; Dinh et 
al., 2017). The results using R6G provide no direct information regarding the 
contributions of the different cell types to the measured R6G lung uptake and estimated 
Δm, although endothelial cells would be expected to dominate because of their large 
surface area and high fraction (~50%) of total lung cells, and their direct contact with 
R6G in perfusate (Crapo et al., 1980). Although the question regarding the contributions 
of specific cell types will be important for future studies, alteration in the lung R6G 
uptake and estimated Δm  as an index of pulmonary mitochondrial dysfunction has 
functional implications regardless of the lung cell types involved.  
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We and others have reported various measures of mitochondrial dysfunction in 
intact lungs, pulmonary endothelial cells in culture, and isolated mitochondrial in 
response to oxidative stress (Gan et al., 2011; Audi et al., 2017; Sepehr et al., 2013; Gan 
et al., 2011; Ma et al., 2018; Audi et al., 2008; Merker et al., 2007; Pruijn et al., 1992). 
The proposed approach will allow us to quantify the effect of oxidative stress on Δm in 
intact functioning lungs.  
Preliminary results from lungs of rats exposed to hyperoxia show a decrease in 
R6G venous effluent concentration following the addition of FCCP. This suggest that the 
mitochondria in hyperoxic lungs is less coupled as compared to those in control lungs. 
This observation is consistent with the results from studies in mitochondria isolated from 
lungs of rats exposed to hyperoxia for 48 hours, which show a significant decrease in the 
activities of complex I and complex II, and prolonged ADP-stimulated Δm 
depolarization (Audi et al., 2017). Experimental data in the presence of verapamil are 
needed to account for the effect of potential hyperoxia-induced change in Pgp activity on 
R6G venous effluent concentration. 
6.2 Conclusions: 
In conclusion, we present a novel experimental and computational approach for 
probing and estimating Δm in intact lungs. The approach has the potential to provide 
quantitative assessment of the effect of various injurious conditions on lung 
mitochondrial function, and to evaluate the impact of therapies that target the 
mitochondria. The proposed approach can also be easily adapted for other organs or 
cationic dyes. 
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APPENDIX 
A. Preparation of Stock solutions: 
A.1 FCCP Preparation and Fractionation: 
Molecular Weight of FCCP: 254.17 g 
DMSO Solubility: Up to 10 mM 
We have a 10 mg bottle of FCCP 
For a 100 M stock of FCCP, what volume of DMSO is needed? 
- 1 mole of FCCP → 254.17 g 
- ? → 10 ∗ 10−3 g 
𝑥 =  
10∗10−3𝑔∗𝑚𝑜𝑙
254.17 𝑔
= 0.03934 𝑚𝑚𝑜𝑙      (A.1.1) 
100 𝑚𝑀 =  
0.03934 𝑚𝑚𝑜𝑙
𝑥
                     (A.1.2) 
𝑥 =  
0.03934 𝑚𝑚𝑜𝑙
100 
𝑚𝑚𝑜𝑙
𝐿
= 0.3934 𝑚𝐿       (A.1.3) 
For a perfusate concentration of 50 M FCCP: 
- Reservoir volume is 25 mL  
- Add 12.5 L (0.05% DMSO) of stock per 25 mL in reservoir for a final 
concentration of 50 M 
Stock Fractionation: 
- 10 mg → 0.3934 mL DMSO 
- Fractionate → 25 L volumes 
- This gives us a total of 15 vials we can use 
- Freeze 
A.2 Verapamil HCL Preparation: 
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Important Information: 
- Molecular Weight = 491.069 g/mol 
- Soluble in H2O (83 mg/mL) 
- Previous study used 0.1 mM 
1.) 5 mg = 10.18 umol in 10 mL DH2O = 1.018 mM 
2.)  Or add 5 mg to 100 mL perfusate for final concentration of 0.1 mM 
A.3 Preparation of Perfusate: 
0.5% BSA and 2.5% Ficoll 
i. Take BSA jar first out of fridge to cool down before opening it. 
ii. Prepare a bottle of DH2O. 
iii. Take a beaker with the proper volume, label it, and add a stirring stick into it. 
Then Add a proper volume of DH2O, the amount is the total volume minus 50 
mL for each 300 mL. 
iv. Place the beaker on the heater, set the stir as ‘2’ (no heat). 
v. Calculate/add the following chemicals required, for 100 mL (0.5% BSA 2.5% 
Ficoll), 
Add stock in order, weigh the assigned quantity of stuffs, and add them into the 
beaker 
 
Stock (in 
Fridge) 
KCL, 
0.5 mL 
CaCl2 , 
0.5 mL 
MgSO4 , 0.5 
mL 
KH2PO4 , 
0.5 mL 
  
Chemicals 
(on the 
shelves) 
Note: use 
separate 
spatula for 
each 
chemical 
NaCl, 
0.69 g 
Dextrose, 
0.1 g 
Sodium 
Bicarbonate, 
0.21 g 
BSA, 0.5 g Papaverine, 
0.06 g 
Ficoll, 
2.5 g 
Note: Please keep the table clean always. Clean the electronic balance after all 
stuffs have been weighed. 
Note: Papaverine is used as a vasodilator to prevent smooth muscle cells within the 
lung from constricting and therefore increasing pressure which in turn leads to 
edema and tissue death. 
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Note: Addition of Papaverine slightly lowers the pH value. 
vi. Take a glass stir bar and push BSA into solution. 
vii. Put a piece of parafilm on to cover the beaker to prevent contamination and to 
keep it stirring until all BSA is in solution (15-20 min). 
viii. Use a graduated cylinder to bring the solution to the desired volume and then 
place the solution into a clean saline bottle with labels including date and 
contents.  
Note: Place the label on the shoulder of the bottle to prevent from getting wet.  
ix. Empty the beaker content into a plastic bottle. Use a cone (with a cotton 
gauze to filter out any particulate in the Perfusate). 
x. Place the bottle into the warm water bath (37 ᵒC) for ten minutes. 
xi. Prepare the gas mixture in the balloon. 
a.) Take a gas balloon. 
b.) Turn on all the tanks, using fine adjustment valves to set the parameter as 
(settings of stainless steel balls) N2=7, O2=38, CO2=120. 
c.) Close the three-way stopcock to the balloon and begin filling the balloon with 
the gas mixture for about 5 minutes. Then insert a cork into the tubing and turn 
off all the tanks.  
d.) Withdraw a syringe of mixture gas in the balloon, and check the gas ingredients 
with the blood gas analyzer. Reference value: O2: 16%, CO2: 5%. 
e.) Cut the tubing long enough to reach from the pump to the bottom of bottle, turn 
the three-way valve open to the balloon. 
f.) Allow the gas mixture to bubble for about 20 minutes, check the pH at intervals 
– use a syringe with long needle, withdraw about 1 mL and check the pH with 
the blood gas analyzer. Reference Value: O2:120-140 mmHg, Co2: 35-40 
mmHg and pH: 7.4. 
Note: If the pH is high, then keep bubbling, if the pH is too low, then prepare for 
another gas balloon without CO2 and bubble the Perfusate with this gas mixture.  
g.) When BSA is ready, begin to prepare for other stuffs and the perfusion system. 
𝐶𝑂2 + 𝐻2𝑂 ↔ 𝐻2𝐶𝑂3 ↔ 𝐻𝐶𝑂3
− + 𝐻+ 
Law of pH 
>7.4: too little hydrogen and too much CO2 
 - bubble w/ CO2 to drive reaction. 
<7.4: too much hydrogen and too little CO2 
 - bubble w/ air to drive reaction. 
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A.4 R6G Stock Procedure: 
Note: Prepare and use solutions on the same day. However, if there is a need to 
make up stock solutions in advance, it is recommended that you store the 
solution as aliquots in tightly sealed vials at -20°C. These solutions will be 
viable for up to one month. Allow the solution to equilibrate to room 
temperature for at least 1 hour before using. 
• Molecular weight of R6G: 479.02 g/mole 
• Mix 1 mg R6G powder with 1 mL H2O to make Stock 1 
- This yields a concentration of 2.09 mM 
• Then dilute by taking 40 uL of the stock and add it to 1.96 mL H2O to make 
Stock 2 
- This gives a stock concentration of 41.8 uM 
- Now add 0.7177 mL of Stock 2 to 120 mL perfusate to get an R6G 
concentration of 0.25 uM in the perfusate 
B. PTI Software Setup: 
1) Open the Felix software. 
2) Select the Rhodamine 6G macro. 
3) Select ‘Set up’. 
4) Select ‘Time based’ 
5) Select the acquisition settings tab in the set-up window. 
6) Switch the excitation wavelength to 525 nm. 
7) Change the acquisition time to 2000 seconds. 
C. Experimental setup/procedure: 
R6G Single Pass Experiment 
Materials Needed: 
• Dark marker for labeling 
• One beaker labeled for perfusate only 
• One beaker labeled for R6G and perfusate 
• One beaker labeled for R6G, perfusate, and verapamil 
• Plastic beaker for waste 
• One beaker and one squirt bottle for deionized water  
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• Large and smalls syringes with tubing for rinsing cuvette 
• R6G stock  
• Verapamil and/or FCCP 
• 2.5% Ficoll-Krebs/0.5% BSA perfusate 
• (74 - 1.7mL) Eppendorf tubes for samples to be centrifuged in 
o 42 for single pass, 8 for wash, and 24 for uncoupler. Have extras on hand. 
• Micropipettes (two P1000’s for 717.7 L and 1000 L and one P200 for FCCP) 
• Labels for eppendorf tubes need to be the same as timer (no time for 
conversions during experiment) 
• Stirring rod 
• Extra eppendorf holder for eppendorfs used during collection 
• Cuvette vacuum cleaner device 
Methods:  
Excitation Wavelength: 525 nm 
Emission Wavelength: 565 nm 
Notes: Then take the cuvette measurements at the end of the experiment. Make sure 
all equipment is turned on and warmed up 30 minutes prior to experiment (i.e. 
water bath). Practice time callouts before IPRL experiment.  
If using Verapamil: 
• Wash with regular perfusate for 5 minutes to rinse out any R6G and/or blood 
• Add Verapamil to perfusate without R6G 
• Flow: 10 mL/min 
• Recirculate for 3 minutes  
• Then turn the pump off  
• Drain the perfusate 
• Begin procedure below but add verapamil perfusate to the system 
If not using Verapamil: 
• Turn pump off 
• Add 717.7 L R6G stock to 120 mL perfusate (0.02 mg/mL) = 0.25 M 
• Stir with glass stirring rod 
• Add perfusate w/o R6G to reservoir 
• Take “Background” sample now from the normal perfusate (use 2 - 1.7 mL 
eppendorf tubes)  
• Drain the perfusate w/o R6G from the reservoir 
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• Add 50 mL perfusate w/R6G to the reservoir then continuously add more to 
keep reservoir from becoming empty and allowing air to enter the system 
• Take “0” sample now (use 2 - 1.7 mL eppendorf tubes) 
• Turn pump on 
• Draw samples out at 40 seconds, 60 seconds, 1:20, 1:40, 2, 2:20, 2:40, 3, 3:20, 
3:40, 4, 4:20, 4:40, 5, 6, 7, 8, 9 and 10 minutes (use 2 - 1.7 mL eppendorf tubes 
per sample time)  
• With flow rate of 10 mL/min fill tubes for 6 seconds each. 
o Do this by taking samples 6 seconds before and after the times stated above. 
• Stop the flow and wash the reservoir (perform this as quickly as possible). 
• Rinse the system/lung for 3 minutes (single pass) with perfusate without R6G. 
o Make sure to get a new baseline for each new condition (i.e. wash) before 
turning the pump back on. 
o Measure for 3 minutes taking samples at 1, 2, and 3 minutes (use 2 - 1.7 mL 
eppendorf tubes per sample time) 
• Stop the flow and wash the reservoir (perform this as quickly as possible). 
• Next add the uncoupler (FCCP) to perfusate without R6G and measure the 
effects. 
o Make sure to get a new baseline for each new condition (i.e. FCCP) before 
turning the pump back on. 
o Measure for 7 minutes taking samples at 13:20, 13:40, 14, 14:20, 14:40, 15, 16, 
17, 18, 19, and 20 minutes (use 2 - 1.7 mL eppendorf tubes per sample time) 
• All samples are spun for 1 minute in the centrifuge @ 10.5 x 1,000 RPM @ 4ᵒC 
• Add each time sample (from 2 eppendorf tubes) to a single cuvette and measure 
for fluorescence. 
• Make sure to use only one cuvette but rinse it with deionized water before 
taking any measurements.  
D. Standard Curve: 
Materials Needed: 
• Cuvette 
• Micropipettes (two P1000’s for 1 mL and 0.25 mL, one p5000 for 2.25 mL, and 
one P100 for 53.82 L) 
• 5 large tubes for doing the mixing/dilution 
• 2.5% Ficoll-Krebs/0.5% BSA perfusate 
• (12 - 1.7mL) Eppendorf tubes for samples to be centrifuged in 
• Labels for eppendorf tubes 
• Extra eppendorf holder for collection eppendorfs 
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Methods:  
• Get “zero” sample of perfusate without R6G 
• Add 53.82 L of R6G Stock 2 to 4.5 mL of perfusate in a large tube to get a 
concentration of 0.5 M  
• Dilute by taking 2.25 mL of the perfusate w/ R6G and mixing it with 2.25 mL 
of the perfusate w/o R6G to get a concentration of 0.25 M 
• Dilute by taking 2.25 mL of the previous perfusate w/ R6G and mixing it with 
2.25 mL of the perfusate w/o R6G to get a concentration of 0.125 M 
• Dilute by taking 2.25 mL of the previous perfusate w/ R6G and mixing it with 
2.25 mL of the perfusate w/o R6G to get a concentration of 0.0625 M 
• Dilute by taking 2.25 mL of the previous perfusate w/ R6G and mixing it with 
2.25 mL of the perfusate w/o R6G to get a concentration of 0.03125 M 
• Now place 1 mL in each eppendorf tube (2) per concentration 
• Then place them symmetrically in the centrifuge for 1 minute @ 10. 5 x 1,000 
RPM @ 4ᵒC 
• Use single cuvette and rinse before each measurement with deionized water 
• Make sure to start with lowest concentrations first and end with highest 
concentrations to avoid harmful binding effects 
• Place supernatant (from 2 eppendorf tubes per concentration) into cuvette and 
take sample of fluorescence  
• Use data to create standard curve in sigma plot or excel 
E. Matlab Code: 
E.1 r6g_single_pass_sim.m  
function r6g_single_pass_sim 
%% 
clear all 
close all 
clc 
global deltap F 
%% Values of model parameters 
vmaxkm = 13.989154; %18.7;% Kpgp Rate of efflux of R6G from pgp pump 
(ml/min)    
k2_bar = 11.147875;% Apparent rate constant for R6G-Bc binding within the 
cytoplasm region(min-1) 
kminus2 = 0.093307;%Dissociation rate constant of R6G-Bc binding within the 
cytoplasm region (uM-1*min-1) 
kd3 = 0.019121;%Dissociation equilibrium constant for dye-protein binding in 
the mitochondria region (umol-1*min-1) 
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ps2 = 0.837797;% dye permeability-surface area product across mitochondria 
membrane (ml/min) 
deltam = 122.558453; % Mitochondrial membrane potential (mV)  
deltam_un =0.1; %68; % mitochondrial membrane potential after uncoupler is 
added (mV) 
  
%fixed 
deltap = 43; %40 Plasma membrane potential (mV) 
F = 10; %Flow (ml/min) 
%%--------------- 
% plot(tt,blood_tissue_region) 
Ce_bar = 0; %Total initial vascular R6G concentration (uM) 
Cc = 0; %Total initial tissue R6G concentration (uM) 
Cm = 0; %Total initial mitochondrial R6G concentration (uM) 
CcBc = 0; % Total intial bound r6g cytoplasm concentration (uM) 
Ctub1 = 0; % Total intial tubing r6g concentration (uM) 
%Ctub2 = 0; % Total intial tubing r6g concentration (uM) 
%Ctub3 = 0; % Total intial tubing r6g concentration (uM) 
%Ctub4 = 0; % Total intial tubing r6g concentration (uM) 
% show the values of parameters during optimization process 
% parameter_values = p; 
parameter_values(1) = ps2; 
parameter_values(2) = k2_bar; 
parameter_values(3) = kminus2; 
parameter_values(4) = kd3; 
parameter_values(5) = deltam; 
parameter_values(6) = deltam_un; 
parameter_values(7) = vmaxkm; 
  
  
%% calling to function solving ODE's 
ttdata = [0:0.1:20]'; 
options=odeset('InitialStep',1e-10,'RelTol',1e-10,'Refine',-
1);%,'NormControl','on'); 
  
% temp = parameter_values; 
x0 = [Ctub1 Ce_bar Cc Cm CcBc]; % mass/volume aka concentration input 
calculated based off real experimental values (uM) 
  
% calling to ode 
[tfinal,xfinal] = ode45(@r6g_odes, ttdata, x0, options, parameter_values); 
  
%% open file, read experimental data to be fit 
figure 
plot(tfinal, xfinal(:,2), ttdata, xfinal(:,2)) 
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infile = 'sim.txt';  
 fid = fopen(infile, 'w');   
%% read data from fil 
  
for i=1:length(ttdata) 
fprintf(fid,'%f %f\n', tfinal(i), xfinal(i,2)); 
end 
 fclose(fid); 
%get data  
E.2 r6g_odes.m 
function [ x_dot ] = r6g_odes(ttdata,x, parameters) 
  
global deltap F 
  
% define parameters  
Ve = 0.85; %Physical lung vascular volume = 1 ml 
Vc = 1; %Physical lung tissue volume = 1 ml 
Vm = 0.02*Vc; %Physical lung mitochondrial volume = 0.01*Vc (ml) 
Vtub = 4; % measured Physical tubing volume (ml) 
alpha = 0.0374158; %ZF/RT   where Z is the valency of the ions (Na+, Ca2+, and 
Cl-), F is Faraday’s constant ... 
...(9.684 x 104 C/ mol), R is the gas constant (8.135 J/K*mol), and T is the 
absolute temperature in K (273 + temp in Celcius). (mV-1) 
Be = 0.5; %[BSA]    Total vascular protein (BSA) concentration (uM) 
kd1 = 0.32;%15; %k-1/k1   %Dissociation equilibrium constant for dye-protein 
binding in the vascular region (umol-1*min-1) 
ps1 = 50.558129; 
  
%%%%%%%%%%%%%%%%%    
ps2         = parameters(1);    
k2_bar      = parameters(2); 
kminus2     = parameters(3); 
kd3         = parameters(4); 
deltam      = parameters(5); 
deltam_un   = parameters(6); 
vmaxkm      = parameters(7);   
  
% calculate the apparent volumes 
V3 = Vm*(1+(1/kd3));    %Apparent mitochondrial volume (ml) 
  
%create vector of zeros 
x_dot = zeros(5,1); 
  
% get last time point from data gathered 
time = 20; 
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% varying Cin based off phase and deltam 
if ttdata >= 0 && ttdata <= (time-9.6) % phase 1... loading phase 
    Cin = 0.25; 
elseif ttdata > (time-9.6) && ttdata <= (time-6.6) % phase 2... wash phase 
    Cin = 0; 
elseif ttdata > (time-6.6) % phase 3... uncoupler phase 
    Cin = 0; 
    deltam = deltam_un;     %Mitochondrial membrane potential (mV) 
end 
  
% Free concentration of r6g within the vascular region 
Ce = (x(2)/(1+(Be)/(kd1))); %units = nmol/mL or umol/L 
  
% calculate flux values 
J1 = ((alpha*ps1*deltap)/(exp(alpha*deltap)-1))*(exp(alpha*deltap)*Ce-x(3));    
%Dye flux across plasma membrane (nmol/min) 
J2 = ((alpha*ps2*deltam)/(exp(alpha*deltam)-1))*(exp(alpha*deltam)*x(3)-x(4));  
%Dye flux across inner mitochondrial membrane (nmol/min) 
  
% ODE's - do differential computations here 
x_dot(1,1) = (1.0/(Vtub))*F*(Cin-x(1)); % tubing region  
x_dot(2,1) = (1/Ve)*(-J1+vmaxkm*x(3)+F*(x(1)-x(2))); % extracellular/vascular 
region units = nmol/mL*min 
x_dot(3,1) = kminus2*x(5)-k2_bar*x(3)+(1/Vc)*(J1-J2-vmaxkm*x(3)); % 
cytoplasm region free 
x_dot(4,1) = (1/V3)*(J2); % mitochondrial region units = nmol/mL*min 
x_dot(5,1) = k2_bar*x(3)-kminus2*x(5); % cytoplasm region bound 
  
end 
E.3 r6g_fit_v3_single.m  
function r6g_fit_v3 
  
% % initial cleanup 
clear all  
close all 
clc 
  
global deltap F tt deltam_un 
 %% open file, read experimental data to be fit 
infile = 'conc_data_041018.txt';  
  fid = fopen(infile, 'r');   
%% read data from file 
 data150 = textscan(fid,'%f %f'); 
 fclose(fid); 
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%get data  
  tt = (data150{1}); 
 blood_tissue_region=(data150{2}); 
  
% plot(tt,blood_tissue_region) 
figure 
plot(tt, blood_tissue_region) 
  
%% initialize and do lsqcurvefit 
         
    % define the data which will be used to estimate parameters  
    indata = [blood_tissue_region]; 
     
    % define the corresponding sampling time points 
    ttdata = [tt]; 
     
%%%%% 
 figure 
     subplot(2,1,1) 
     plot(ttdata,indata,'ko') 
%     legend('Data','Fitted Curve') 
     title('Data and Fitted Curve from Residuals') 
     xlabel('Time (minutes)') 
     ylabel('Concentration (uM)')   
      
hold on 
for i =1:1 
%% define initial values for the unknown parameters 
vmaxkm = 8.840851;% Kpgp Rate of efflux of R6G from pgp pump (ml/min)    
k2_bar = 12.475779;% Apparent rate constant for R6G-Bc binding within the 
cytoplasm region(min-1) 
kminus2 = 0.110531;%Dissociation rate constant of R6G-Bc binding within the 
cytoplasm region (uM-1*min-1) 
kd3 = 0.02313;%Dissociation equilibrium constant for dye-protein binding in the 
mitochondria region (umol-1*min-1) 
ps2 = 0.83082;% dye permeability-surface area product across mitochondria 
membrane (ml/min) 
deltam = 123.11; % Mitochondrial membrane potential (mV)  
deltam_un = 0.1; % mitochondrial membrane potential after uncoupler is added 
(mV) 
ps1 = 49.4309;   
%fixed 
deltap = 43; %40 Plasma membrane potential (mV) 
F = 10; %Flow (ml/min) 
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    % define the optimization options 
    options = optimset('Algorithm', 'trust-region-reflective', 'MaxFunEvals', 3000, 
'TolFun', 1e-15,'TolX',1e-10); 
  
%% no verapamil fitting         
 % define the parameters which will be estimated 
    p0 = [ps2, k2_bar, kminus2, kd3, deltam, vmaxkm, ps1]; 
           
    % define the lower bound of parameters 
    %lb = 0.0001*ones(length(p0),1);  
    lb = [0.0001, 0.0001, 0.0001, 0.0001, 110, 0, 0.001];  
     
    % define the upper bound of parameters 
   % ub = [200 200 200 200 200 200 1  200];% 
    ub = 300*ones(length(p0),1); %[20 20 20 20 20 20];  
% fitting model to input data and find out the optimized values for parameters 
[p, ssd, residual, ef, outt,lambda, jacobian] = 
lsqcurvefit(@r6g_single_pass_param_est_v3, p0, ttdata, indata, lb, ub, options); 
%%%%%% 
PPAR(i,1) = p(1); 
PPAR(i,2) = p(2); 
PPAR(i,3) = p(3); 
PPAR(i,4) = p(4); 
PPAR(i,5) = p(5); 
PPAR(i,6) = p(6); 
PPAR(i,7) = p(7); 
  
fit_conc = indata+residual; 
  
     plot(ttdata, fit_conc,'b-') 
    
  
end 
p(1) = mean(PPAR(:,1)) 
p(2) = mean(PPAR(:,2)) 
p(3) = mean(PPAR(:,3)) 
p(4) = mean(PPAR(:,4)) 
p(5) = mean(PPAR(:,5)) 
p(6) = mean(PPAR(:,6)) 
p(7) = mean(PPAR(:,7)) 
  
%%%%%% 
PPAR(:,1) 
PPAR(:,2) 
PPAR(:,3) 
PPAR(:,4) 
87 
PPAR(:,5) 
PPAR(:,6) 
PPAR(:,7) 
    % residual = model fit - data 
          
    % 
    %correlation matrix 
NP = length(p0); 
h = inv(jacobian'*jacobian); 
for i = 1:NP; 
 for j = 1:NP; 
 cc(i,j) = h(i,j)/((h(i,i)*h(j,j))^0.5); 
 end 
end 
full(cc) 
  
%confidence intervals (95% confidence, alpha = 0.05) 
s_2 = ssd/(length(indata) - NP); 
for i = 1:NP; 
 seb(i) = ((s_2)^0.5)*(h(i,i)^0.5); 
end 
alpha = 0.05; 
tt_dis = - tinv(alpha/2, length(indata) - length(p0)); % tinv is the Student's t 
inverse cumulative 
  
%distribution function 
seb = seb.*tt_dis; 
seb 
%%%%%%%% 
     
     figure 
     plot(ttdata, jacobian(:,1)) 
%    figure 
%     plot(ttdata, jacobian(:,2)) 
%     figure 
%     plot(ttdata, jacobian(:,3)) 
%     figure 
%     plot(ttdata, jacobian(:,4)) 
     figure 
     plot(ttdata, jacobian(:,5)) 
%     figure 
%     plot(ttdata, jacobian(:,6)) 
%     figure 
%     plot(ttdata, jacobian(:,7)) 
%     figure 
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    % display the optimized values of parameters and related results 
%     fprintf('result:\n   PS1 = %f +/- %f ml/min\n', p(1), ci(1,1)); 
    fprintf('   PS2 = %f ml/min\n', p(1)); 
%     fprintf('   kd1 = %f +/- %f Percent BSA\n', p(3), ci(1,3)); 
    fprintf('   k2_bar = %f min-1\n', p(2)); 
    fprintf('   kminus2 = %f min-1\n', p(3));     
    fprintf('   kd3 = %f  uM\n', p(4)); 
    fprintf('   deltam = %f mV\n', p(5)); 
   % fprintf('   deltam_un = %f  mV\n', p(6));    
    fprintf('   VmaxKm = %f ml/min\n', p(6)); 
       fprintf('   ps1 = %f ml/min\n', p(7)); 
%     fprintf('   deltap = %f +/- %f mV\n', p(8), ci(1,8)); 
    fprintf('   deltap = %f mV\n', deltap); 
    fprintf('   SSD = %f\n', ssd);   
  
    end 
E.4 r6g_single_pass_param_est_v3.m 
function Out = r6g_single_pass_param_est_v3(p, ttdata) 
  
global deltap F tt deltam_un 
  
%% Initial values for ODEs 
  
Ce_bar = 0; %Total initial vascular R6G concentration (uM) 
Cc = 0; %Total initial tissue R6G concentration (uM) 
Cm = 0; %Total initial mitochondrial R6G concentration (uM) 
CcBc = 0; % Total intial bound r6g cytoplasm concentration (uM) 
Ctub1 = 0; % Total intial tubing r6g concentration (uM) 
%Ctub2 = 0; % Total intial tubing r6g concentration (uM) 
%Ctub3 = 0; % Total intial tubing r6g concentration (uM) 
%Ctub4 = 0; % Total intial tubing r6g concentration (uM) 
% show the values of parameters during optimization process 
% parameter_values = p; 
parameter_values(1) = p(1); 
parameter_values(2) = p(2); 
parameter_values(3) = p(3); 
parameter_values(4) = p(4); 
parameter_values(5) = p(5); 
parameter_values(6) = p(6); 
parameter_values(7) = p(7); 
%parameter_values(8) = p(8); 
  
%% calling to function solving ODE's 
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options=odeset('InitialStep',1e-10,'RelTol',1e-10,'Refine',-
1);%,'NormControl','on'); 
  
% temp = parameter_values; 
x0 = [Ctub1 Ce_bar Cc Cm CcBc]; % mass/volume aka concentration input 
calculated based off real experimental values (uM) 
  
% calling to ode 
[tfinal,xfinal] = ode45(@rhodamine6GSolver_single_pass_param_est_v3, ttdata, 
x0, options, parameter_values); 
  
Out = xfinal(:,2); 
E.5 rhodamine6GSolver_single_pass_param_est_v3.m 
function [ x_dot ] = rhodamine6GSolver_single_pass_param_est_v3(ttdata,x, 
parameters) 
  
global deltap F tt deltam_un 
  
% define parameters  
Ve = 0.85; %Physical lung vascular volume = 1 ml 
Vc = 1.0; %0.67; %Physical lung tissue volume = 1 ml 
Vm = 0.02*Vc; %Physical lung mitochondrial volume = 0.01*Vc (ml) 
Vtub = 4; % measured Physical tubing volume (ml) 
alpha = 0.0374158; %ZF/RT   where Z is the valency of the ions (Na+, Ca2+, and 
Cl-), F is Faraday’s constant ... 
...(9.684 x 104 C/ mol), R is the gas constant (8.135 J/K*mol), and T is the 
absolute temperature in K (273 + temp in Celcius). (mV-1) 
Be = 0.5; %[BSA]    Total vascular protein (BSA) concentration (uM) 
kd1 = 0.32; %0.306430;%15; %k-1/k1   %Dissociation equilibrium constant for 
dye-protein binding in the vascular region (umol-1*min-1) 
%ps1 = 63.551726; 
  
%%%%%%%%%%%%%%%%%    
ps2         = parameters(1);    
k2_bar      = parameters(2); 
kminus2     = parameters(3); 
kd3         = parameters(4); 
deltam      = parameters(5); 
%deltam_un   = parameters(6); 
vmaxkm      = parameters(6);   
ps1         = parameters(7);  
% calculate the apparent volumes 
V3 = Vm*(1+(1/kd3));    %Apparent mitochondrial volume (ml) 
  
%create vector of zeros 
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x_dot = zeros(5,1); 
  
% get last time point from data gathered 
time = tt(end); 
  
% varying Cin based off phase and deltam 
if ttdata >= 0 && ttdata <= (time-9.6) % phase 1... loading phase 
    Cin = 0.25; 
elseif ttdata > (time-9.6) && ttdata <= (time-6.6) % phase 2... wash phase 
    Cin = 0; 
elseif ttdata > (time-6.6) % phase 3... uncoupler phase 
    Cin = 0; 
    deltam = deltam_un;     %Mitochondrial membrane potential (mV) 
end 
  
% Free concentration of r6g within the vascular region 
Ce = (x(2)/(1+(Be)/(kd1))); %units = nmol/mL or umol/L 
  
% calculate flux values 
J1 = ((alpha*ps1*deltap)/(exp(alpha*deltap)-1))*(exp(alpha*deltap)*Ce-x(3));    
%Dye flux across plasma membrane (nmol/min) 
J2 = ((alpha*ps2*deltam)/(exp(alpha*deltam)-1))*(exp(alpha*deltam)*x(3)-x(4));  
%Dye flux across inner mitochondrial membrane (nmol/min) 
  
% ODE's - do differential computations here 
x_dot(1,1) = (1.0/(Vtub))*F*(Cin-x(1)); % tubing region  
x_dot(2,1) = (1/Ve)*(-J1+vmaxkm*x(3)+F*(x(1)-x(2))); % extracellular/vascular 
region units = nmol/mL*min 
x_dot(3,1) = kminus2*x(5)-k2_bar*x(3)+(1/Vc)*(J1-J2-vmaxkm*x(3)); % 
cytoplasm region free 
x_dot(4,1) = (1/V3)*(J2); % mitochondrial region units = nmol/mL*min 
x_dot(5,1) = k2_bar*x(3)-kminus2*x(5); % cytoplasm region bound 
  
end 
